

Specialty Chemicals Annual Report Analysis

Promoters still bullish; Indian chemicals story strong

Contents

Contents	Page no
Indian Specialty Chemicals Sector	3-4
Valuation	5
SRF	6
Vinati	7
Fine Organic	8
Navin Fluorine	9
Deepak Nitrite	10
Atul	11
Revenue Analysis	12-14
Gross Margin Analysis	15-16
Power & Fuel cost	17
Freight and Forwarding expenses	18
Employee and other expenses Analysis	19
EBITDA	20
Depreciation	21
Other Income	22
Finance Cost	23
Profit after Tax	24-25
Debt	26
Capex to OCF	27-28

Contents	Page no
Capex Plan	29
Cash-Conversion cycle	30-31
Inventory Analysis	32-33
Receivables (Provision for Doubtful Debts)	34-35
OCF Analysis	36
FCF Analysis	37
Cash, Bank and Investments, as % of capital employed	38-39
R&D	40-41
Remuneration to Directors, KMP	42-47
Navin's MDA	48-52
Vinati's MDA	53-56
Deepak Nitrite's MDA	57-65
Fine Organic's MDA	66-71
SRF's MDA	72-77
Atul's MDA	78-84
Contingent Liabilities	85
Focus on ESG	86-89
Dividend Pay-out	90
Promoters' Holdings	92
Related-Party Transactions	93-95

We analyzed the FY22 annual reports of six chemicals companies (SRF, Vinati Organics, Fine Organic, Navin Fluorine, Deepak Nitrite and Atul). The Covid-19 pandemic impact, widespread supply bottlenecks, non-availability of key raw materials, higher energy and raw material prices were key challenges in FY22. The companies' strong revenue growth came from higher realizations and volumes on the low base. Despite the topline growth, EBITDA margins were hurt by lower gross margins (higher raw material costs not fully absorbed), higher power & fuel costs (energy crisis) and higher freight & forwarding expenses (logistic challenges and container non-availability). Ahead, the companies are positive on the long-term structural growth of the Indian chemicals sector on the back of the China+1 strategy, focus on reducing chemical imports, R&D capabilities, and its leading and strong position with favourable government policies.

Supply diversification from China; growth trigger for Indian chemicals companies. With supply-chain disruptions and uncertainty in China, global manufacturers are seeking to diversify their sourcing. India provides strong alternatives with scale, technology, raw materials and supportive government policies. India's chemicals sector is in a good position to profit from this change and capture a sizable share of the market. Indian chemicals manufacturers are poised to emerge as a credible alternative and, in some cases, primary suppliers to global firms. While all in the Indian chemicals sector would benefit from this shift, specialty chemicals manufacturers could gain the most due to higher entry barriers and potential for value-added niche products.

Navin and SRF in a sweet spot in fluorine chemistry. The fluorochemicals sub-segment is expected to record a 5.2% CAGR to \$25.1bn between now and 2026. Fluorinated organic compounds are of interest in the pharmaceutical and agrochemical sectors. Navin intends to deepen its R&D capabilities, in the development process of a new product around the fluoropyridine platform, expecting to emerge as the first such producer in India with multi-year revenue possibilities. Further, is targeting approval of its R22 PTFE samples. SRF will continue to invest in its chemicals business to sustain healthy growth rates over the next few years. Collaboration with major global innovators for process development, commercialisation, and production of complex, new-age molecules with downstream applications in agro and pharma would support growth. With huge capex in polytetrafluoroethylene (PTFE), chloromethane, etc. likely to be capitalised in the next few quarters, it is looking forward to exciting times ahead in fluorochemicals.

Vinati and Deepak; focus on import substitution. Vinati, a market leader in key specialty chemicals, is on track to further expand its niche range of products, enabling import substitution. Deepak Nitrite, from its first product 'sodium nitrate' to its latest foray into 'phenol and acetone, aligned its focus on products where domestic demand was largely import-dependent. Import substitution has always been a major driver of the company's overall business plan. Deepak continues to focus on launching value-added downstream products with the goal of substituting imports primarily to capitalize on the more favourable demand context.

Fine Organic's focus on growth and sustainability. Demand for oleochemicals-derived additives is increasing as consumers want more environment-friendly and “green” products. Fine Organic's green additives have been effectively replacing potentially hazardous chemicals in a wide range of industries such as plastics, packaging, foods, cosmetics, rubbers and coatings. Minimized waste generation, effluent management through effective production processes, use of natural gas and stringent compliance with regulations continue to be focus areas of sustainability. The company is intending to expand operations in Gujarat, focusing on expanding facilities for new and present product lines with process improvements and technology upgrades.

Atul is focusing more on improving manufacturing and working-capital efficiencies, adding capacity through de-bottlenecking existing capacities. Further, it aims to add more products in different sub-segments and widen its market reach in new regions. It is looking at inorganic growth opportunities in aromatics and evaluating investment opportunities in vertical integration.

Our View. In the last 2-3 years, Indian chemicals companies have been re-rated 2-3x on strong earnings growth given better pricing, stable crude oil prices and benefits from the China+1 policy. Long term outlook is positive on the sector as the fundamentals remains strong. Companies are guiding to huge capex (Aarti Rs12bn-15bn annually for the coming years), Navin (~Rs15bn over FY22-FY23), SRF (Rs15bn-20bn annually), Atul (~Rs15bn), Deepak Nitrite (~Rs20bn in FY23) and many more. For supplies, international manufacturers are preferring India to China considering the latter's R&D abilities, compliance with environment norms and better products. These are the prime factors for the bright outlook. Companies are entering new product lines focusing on import substitution. Hence, despite near-term headwinds, we are structurally bullish on the long-term growth of Indian chemicals companies.

Risk and concerns. Disrupted recovery, higher inflation, rise in energy cost, fluctuation in raw material prices, and supply-chain bottlenecks are key short-term concerns.

Names	Rating	CMP (Rs)	TP (Rs)	M Cap (Rs bn)	EPS (Rs)			P/E (x)			EV/EBITDA (x)			RoE(%)		
					FY22	FY23e	FY24e	FY22	FY23e	FY24e	FY22	FY23e	FY24e	FY22	FY23e	FY24e
SRF *	NR	2,514	NR	744	63.7	77.4	89.3	39.5	32.5	28.2	24.9	20.6	17.8	24.5	22.2	21.1
Aarti	Buy	812	960	294	19.1	25.1	32.0	42.6	32.4	25.3	16.4	20.0	15.9	27.8	14.4	16.2
Deepak Nitrite *	NR	2,087	NR	284	78.2	79.1	93.2	27.0	26.4	22.4	17.7	17.4	14.9	37.5	27.9	25.9
Atul	Buy	8,953	10,145	264	204.8	271.8	338.1	43.7	32.9	26.5	27.8	21.7	17.1	14.6	16.9	18.0
Navin	Hold	4,388	4,650	217	53.1	71.6	110.5	82.6	61.2	39.7	61.1	41.1	27.8	15.1	17.9	23.3
Vinati	Hold	2,047	2,350	210	33.7	45.7	58.3	60.7	44.8	35.1	48.3	34.4	26.8	20.6	23.2	24.2
Fine organic	Sell	7,009	5,145	215	84.7	136.7	114.3	82.8	51.3	61.3	58.5	37.3	43.3	30.7	36.7	23.6
Galaxy Surfactants	Hold	3,051	3,500	108	74.1	76.8	99.8	41.2	39.7	30.6	27.9	24.8	19.6	16.7	15.3	17.2
Nocil	Hold	249	296	41	10.6	13.6	16.2	23.5	18.3	15.4	14.2	11.6	9.6	12.9	14.8	15.7
Neogen	Hold	1,441	1,572	36	17.8	25.1	33.5	80.7	57.5	43.1	42.7	32.6	25.7	14.3	13.4	15.8
Sudarshan	Buy	414	585	29	18.8	16.7	29.3	22.0	24.7	14.1	13.3	12.0	8.2	16.5	13.3	20.6

- ❑ **Revenue grew** 48% y/y to Rs124bn, supported by strong performances of each business category. Despite the Covid-19 pandemic, widespread supply bottlenecks and increasingly higher energy & RM prices, operational and financial performances were robust.
- **Revenue from its chemicals business** grew 44% y/y to Rs52.4bn. Specialty chemicals did remarkably well, driven by strong demand in export and domestic markets. The wider product range helped strengthen and increase customers. Sales of the pharma propellant under the brand Dymel® HFA 134a/P significantly increased, expanding to new regions and consolidating customers across the globe.
- **The packaging films business** grew 45% y/y to Rs48bn. Domestic and international plants delivered strong performances and contributed to overall growth.
- **The technical textiles business** revenue grew 68% y/y to Rs21bn on highest sales volumes from belting fabrics and polyester industrial yarn. This partially offset weak demand for nylon tyre-cord fabrics.
- ❑ **Margin and profits.** SRF maintained its gross and EBITDA margins at 51.2% and 25% respectively vs 52.2% and 25.4% in FY21. Its technical textiles and chemicals business EBIT margins improved a strong ~834bps and 668bps y/y respectively to 22.6% and 26.7% on the better pricing, demand and product mix. The margin in its packaging film business declined 748bps y/y to 19.8%. Profit growth (63.5% y/y to Rs18.9bn) was higher than revenue growth (48% y/y to Rs124bn) as it had a Rs727m forex gain (Rs119m in FY21), maintained its EBITDA margin, had lower interest expense (on capitalisation of debt cost on capex), though partially hurt by higher tax expenses. The net profit margin improved ~100bps to 15%.
- ❑ **Balance sheet.** SRF's cash-conversion cycle lengthened to 55 days due to fewer payable days (126 in FY22 vs 144 in FY21). Further, its inventory days shortened by four to 129 while receivable days were 53 vs 55 in FY21. The net D/E ratio improved to 0.3x (vs 0.4x in FY21) despite adding Rs1.9bn debt in the year. Cash, bank and investments as percent of capital employed was 6% (having averaged 5% in the last eight years). Contingent liabilities were Rs10.2bn (12% of net worth; FY21: Rs8.1bn, 12%) including capital commitments.
- ❑ **Cash-flow.** Consolidated operating cash-flow increased to Rs21bn, from Rs17.7bn in FY21, due to greater profitability and better working capital. Free cash-flow was Rs2.9bn (Rs5.6bn in FY21) due to Rs18bn capex in FY22.

- ❑ **Revenue** grew 69% y/y to Rs16.1bn supported by strong volume growth in H2 FY22. The company reported negative revenue growth in FY20 and FY21. The volume growth on low base and better pricing supported strong revenue growth.
- ❑ **Margin and profits.** In H2 FY22, most businesses' operating margins declined in industry. China cut production due to energy prices and non-availability of major RMs due to supply-chain constraints. Gross margins contracted and operating costs jumped significantly. All of this impacted operating margins of businesses. Besides, operating costs were hit by higher freight costs because of the shortage of containers and higher power and fuel costs on the significant jump in coal and gas prices. Overall, EBITDA margin was down 1,007bps y/y to 26.9%.
- ❑ **Balance sheet.** The cash-conversion cycle shortened to 130 days (from 158 in FY21) due to fewer inventory days (75 in FY22 vs 115 in FY21), partially hurt by a decline in payable days (49 in FY22 vs 63 in FY21). The balance sheet was healthy with the net-debt-to-equity ratio of -0.04x (-0.2x in FY21). Working capital as percent of sales increased to 56.6% during the year vs 54% a year ago (mainly due to loans to related parties). Vinati's cash, bank and investments were 5% of capital employed, compared to 18% in FY21 and an average of 13% in the last seven years as it sold current investments of Rs1.8bn in FY22.
- ❑ **Loan to Veeral Additives Pvt. Ltd.** Vinati gave unsecured loans of Rs1.2bn in FY22 (Rs1.3bn in FY21) to a promoter group company Veeral Additives Pvt. Ltd. at 6.25% interest p.a. to meet the latter's capital/operational expenditure and working capital. Veeral Additives set up a plant to manufacture anti-oxidants for petrochemicals such as HDPE, PP, PS, etc. It will manufacture three products, AO1010, AO1076 and AO168, combined capacity: 24,000 tonnes a year. These are value-added products for Vinati and will constitute forward integration of its products, di-tertiary butyl phenols. While the plant was completed in May'22 and commercial production expected by Sep'22, Veeral Additives will be amalgamated with Vinati. In view of the delay in securing approval from the NCLT for the proposed scheme, Veeral has requested additional funding of up to Rs1bn in FY23; accordingly, the lending limit needs to be raised to Rs3.5bn, from the present approved Rs2.5bn limit.
- ❑ **Cash-flow and Capex,** Despite higher profits, consolidated operating cash-flow declined to Rs1.3bn (from Rs2.2bn in FY21) due to more working capital investments and increased tax rat. Free cash-flow was a negative Rs347m (against Rs1.7bn in FY21) as capex increased to Rs1.6bn in FY22 vs Rs490m in F21.







- ❑ **Revenue growth** was 66% y/y. Supply-chain disruptions and input-price volatility hit the H1 FY22 performance, but H2 growth was exceptional as the company revised its long-term contracts to short-term, coupled with better realization across segments and strong increase in volumes. Further, global supply-chain disruptions, inadequately available raw materials, container shortages and other challenges threw up opportunities, which resulted in surging export demand.
- ❑ **Margins and profit.** Fine Organic's gross margin improved to 36.7% (up 76bps y/y) and its EBITDA margin expanded to 19.4%, up 184bps y/y, driven by better absorption of fixed and power & fuel costs, though more exports led to higher freight and forwarding expenses. PAT growth was exceptional, up 116% y/y, to Rs2.6bn (revenue growth 66%) supported by a higher EBITDA margin (19.4%, vs 17.6% in FY21), lower depreciation expenses 15% y/y to Rs399m (diminishing-value method), lower interest expenses (down 17% y/y to Rs51m) and higher other income, up 93% y/y (forex gain).
- ❑ **Balance sheet.** The cash-conversion cycle lengthened to 84 days (up 17) due to increase in inventory days (72, vs 63 in FY21) and receivable days (59 vs 52 in FY21). Payable days were 47 in FY22 vs 49 in FY21. Fine Organic's net D/E ratio was -0.18x in FY22 vs -0.24x in FY21 due to decline in debt and strong profit growth. Cash, bank and investments as percent of capital employed declined to 23% compared to 32% in FY21 and an average 14% in the last seven years. Contingent liabilities were Rs285m (3% of net worth; FY21: Rs360m, 4.9%) including capital commitments of Rs225m in FY22.
- ❑ **Cash-flow.** Consolidated operating cash-flow declined to Rs670m (from Rs1.3bn in FY21) despite strong profit growth. This was chiefly due to higher working capital. Free cash-flow was Rs59m only (vs Rs880m FY21) due to Rs611m capex in FY22. However, Fine Organic has generated positive average annual FCF of Rs479m over FY15-FY22.

- ❑ **Revenue growth.** On its strong performance in its high-value business, Navin's revenue grew 23% y/y to Rs14.5bn in FY22. Its high-value specialty chemicals and CRAMS business was up 18% y/y. The past refrigerant-gases and inorganic-fluorides business grew 35%, mainly on better price realisation.
 - **CRAMS** revenue grew 6% y/y, to Rs2.9bn, supported by a strong order-pipeline with added customers and projects. The cGMP3 plant ran at optimum capacity utilisation as the company's ability to handle larger projects and complex chemistries significantly improved. Project-flows from customers was strong as Navin continued to widen its reach across global pharma majors.
 - **Specialty chemicals** revenue grew 25% y/y to Rs5.6bn, driven by a mix of new customers & products, and market-share gains. This business saw strong new-project flows from the life-science and crop-science segments and on optimal utilisation of the plant.
 - **Inorganic fluorides** revenue shot up 42% y/y to Rs1.9bn, supported by the low base, better realisations and higher volumes in FY22. The performance had been impacted in H1 and picked up in H2FY22.
 - **Refrigerant business** revenue grew 28% y/y to Rs2.7bn despite phasing out of HCFC-22 (R22) for emissive purposes under the Montreal Protocol. Robust growth was seen due to better price realisation and growth in non-emissives.
- ❑ **Margin and profits.** The EBITDA margin contracted 181bps to 24.4%, from 26.2% a year ago, mainly due to higher utility expenses and employee costs, though partially supported by the stable gross margin. Profit growth (9% y/y to Rs2.6bn) was lower than revenue growth (23% y/y to Rs14.5bn) due to the lower EBITDA margin (higher power and fuel costs, freight and forwarding expenses), and to lower other income (Rs346m interest on an income-tax refund in FY21, Rs53m in FY22), though partially supported by a lower tax rate (23.6% in FY22 vs 31% in FY21).
- ❑ **Balance sheet.** The cash-conversion cycle lengthened to 151 days (137 in FY21) mainly due to more inventory days (up 19 to 141). It was partially supported by higher payable days at 80 (vs 73 in FY21). Navin has taken Rs1bn long-term debt to fund capex, taking the D/E ratio to 0.07x (netD/E -0.04x). In FY22, only 11% of capital employed was lying in the bank (including cash) and in investments (38% in FY21). Contingent liabilities shrank to Rs2.2bn (12% of net worth; FY21: Rs3.9bn, 23.9%) including capital commitments.
- ❑ **Cash-flow.** Consolidated operating cash-flow slipped from Rs2.4bn to Rs748m chiefly due to higher working capital. Free cash-flow for the year was a negative Rs5bn (Rs1.5bn in FY21) due to Rs5.8bn capex and lower OCF.

- ❑ **Revenue growth.** Supported by higher realisations and a better product mix, Deepak Nitrite's revenue grew 56% y/y, to Rs68bn. Its domestic revenue grew 71% y/y to Rs52.7bn. Revenue from exports was Rs15.3bn, up 20%. Its (standalone) domestic-export mix was 58:42.
- **Basic Intermediates (BI).** Despite the adverse macro-economic situation and temporary disruption of raw materials, Deepak met its delivery commitments. Its BI revenue and EBIT grew 66% and 61% respectively to Rs12.6bn and Rs3.1bn.
- **Fine and Specialty Chemicals (FSC)** revenue rose 10% to Rs8.5bn while EBIT was down 23%, impacted by logistic disruptions, elevated RM costs and utilities. Due to the nature of contracts in this sub-segment, prices are not immediately passed on, but with a time lag. Deepak Nitrite expects good demand from end-user segments that would drive further gains in years to come.
- **Performance Products (PP)** revenue grew 74% y/y to Rs5.3bn. EBIT rocketed 335% y/y to Rs1bn. Better DASDA demand resulted to higher realisations. Overall PP volumes rose 26%.
- **Phenolics** revenue grew 68% to Rs42.9bn. The EBITDA was Rs9.7bn with a 23% EBITDA margin. IPA brought 7% to phenolics revenue.
- ❑ **Margin and profit.** The reported lower margin in BI, FSC and phenolics was hit by logistic disruptions, high raw-material costs, temporary disruption in availability and higher utilities. PP margins however expanded on better pricing and favorable demand. The EBITDA margin was down 503bps y/y to 23.6% due to the lower gross margin, more power & fuel expenses, utility and freight & forwarding expenses. Profit was up 37.5% y/y to Rs10.6bn against 56% revenue growth to Rs68bn, hurt by the lower gross margin (33.1% in FY22 vs 42% in FY21), higher depreciation expenses, and partially supported by other income up 98% y/y and interest expenses down 54% y/y.
- ❑ **Balance sheet.** Payable days declined substantially by 25, to 45 days. Further, inventory days shortened by 10, to 52 days. Management says revenue growth and efficient operations led to faster inventory churning, which resulted in fewer inventory days. The cash-conversion cycle lengthened to 67 days (55 in FY21). Deepak has been paying off debt in the last three years. It repaid Rs2.8bn in FY22, taking the net D/E ratio to -0.05x, vs 0.2x in FY21. Cash, bank and investments increased to 13% in FY22 vs 7% in FY21. Contingent liabilities were Rs1.6bn (5% of net worth; FY21: Rs1bn, 4% of net worth) including capital commitments.
- ❑ **Cash flow.** Consolidated operating cash-flow slipped from Rs10bn in FY21 to Rs8.2bn, chiefly due to higher working capital. Free cash-flow for the year was Rs6.4bn (Rs7.9bn in FY21) due to Rs1.8bn capex

- ❑ **Revenue growth.** Better prices and higher sales volumes on a low base on account of the Covid-19 pandemic led to standalone revenue growing 42% y/y to Rs49.3bn. Consolidated revenue grew 36.2% y/y to Rs50.1bn.
 - **Domestic sales** increased 32% to Rs24.8bn while exports shot up ~56% to Rs24.5bn.
 - **Life-Science Chemicals** revenue grew 29% to Rs14.5bn because of higher realizations and greater volumes of crop protection and pharmaceutical intermediates.
 - **Performance and Other Chemicals** sales rose ~49% to Rs34.8bn because of greater sales volume in three sub-segments.
- ❑ **Margin and profit.** Higher raw-material costs, freight & forwarding and power & fuel expenses pulled the EBITDA down 668bps y/y to 17.9%, though it was partially supported by better absorption of employee and other expenses due to higher revenue. Despite 36% revenue growth in FY22, profit declined 8% to Rs6bn due to the lower gross margin, higher depreciation (Rs5.6bn capex) and lower other income (drop in dividend and interest income).
- ❑ **Balance sheet.** Debt was Rs1.4bn (Rs1.3bn in FY21) with the net D/E ratio at -0.25x. The cash-conversion cycle lengthened to 103 days (from 78 in FY21) mainly due to a huge reduction in payable days (down 32, to 89). While receivable days were similar (71 vs 72 in FY21), inventory days declined to 122 (128 in FY21). Of the Rs5.9bn capex, 60% was for the plant and equipment, 4% for land and buildings, and 33% constituted capital WIP. contingent liabilities (incl. guarantees & commitments) were Rs5.5bn (1% of net worth) vs Rs1.8bn in FY21 (5% of net worth).
- ❑ **Cash-flow statement.** Operating cash-flow slipped from Rs7.2bn to Rs2.3bn chiefly due to lower profits and more working capital. FCF was a negative Rs3.6bn (vs Rs3.9bn in FY21) due to higher capex of Rs5.9bn in FY22 and lower OCF.

U-shaped revenue recovery unsustainable (outlier, Navin Fluorine)









U-shaped revenue recovery unsustainable (outlier, Navin Fluorine)

During FY22, major chemicals companies reported strong revenue growth, up from the Covid'19-impacted FY21 and macro-economic challenges globally, which resulted in higher prices of raw materials and finished goods. FY22 revenue growth averaged ~50% for our basket of six companies: SRF, Vinati, Fine Organic, Navin Fluorine, Deepak Nitrite, and Atul.

- ❑ **Vinati Organic** reported the highest revenue of our six companies, 69% y/y, supported by strong volume growth in H2 FY22. It reported negative revenue growth in FY20 and FY21. The high volume growth on low base and better pricing supported strong revenue growth.
- ❑ **Fine Organic**' revenue growth was 66% y/y. Supply-chain disruptions and input-price volatility hit the H1 FY22 performance. However H2 growth was exceptional as the company revised its long-term contracts to short-term, coupled with better realisations in all product segments and some increase in volumes. Further, global supply-chain disruptions, inadequate availability of raw materials, shortage of containers and other challenges have thrown up opportunities and resulted in surging export demand.
- ❑ **SRF's** revenue grew 48% y/y to Rs124bn, supported by strong performances in all businesses. Management said that despite the Covid-19 pandemic, widespread supply bottlenecks and increasingly higher energy and raw material prices, it achieved robust operational and financial performances.
- ❑ **Deepak Nitrite's** revenue grew 56% y/y to Rs68bn, supported by higher realisations and a better product-mix across product categories.
- ❑ **Navin Fluorine's** revenue grew 23% y/y to Rs14.5bn, supported by strong performance continuing in its high-value business and mainly supported by higher volumes than pricing. Specialty chemicals and CRAMS was up 18% y/y. The past business (ref. gases and inorganic fluorides) grew 35% on account of better realisations.
- ❑ **Atul's** standalone revenue grew 42% to Rs49.3bn due to higher prices of inputs and finished goods and low sales in Q1 FY21 hit by the Covid-19 pandemic. Domestic sales increased 32% to Rs24.8bn while exports grew ~56% to Rs24.5bn. Revenue of the Life-science Chemicals segment grew 29% to Rs14.5bn because of higher sale prices and volumes in crop-protection and pharma. Sales of performance chemicals and other chemicals rose ~49% to Rs34.8bn due to higher sales volume in three sub-segments.

Exports vs domestic sales



Gross margins of companies with greater exposure to crude oil severely contracted

The Indian chemicals sector has been faced with challenges related to

- Non-availability of raw materials due to container shortages, logistic challenges, supply issues due to the Russo-Ukraine war, Covid'19-triggered lockdowns and the global challenging environment generally. This resulted in the steep increase in raw material prices
- All these factors resulted in gross margins contracting due to price volatility and the lag in passing them on. The contractions averaged 453bps in FY22 to 46.2%, vs 50.8% in FY21.
- On analysing data, we found that, generally, companies' gross margins declined when revenue growth was driven by higher realisations.


❑ **Vinati, GM down 1,265bps to 46.7%**. Non-availability of major raw materials due to supply-chain constraints and China cutting production due to energy prices resulted in the steep rise in raw material prices.

❑ **Deepak Nitrite, GM down 855bps to 39.5%** The reported lower margins in Basic intermediates, Fine and Specialty Chemicals and phenolics were hit by logistics disruptions, high raw-material costs, an adverse macro-economic situation, temporary disruption in availability and higher utilities. Performance Product margins, however, expanded, supported by better pricing and favourable demand.

❑ **Atul's GM down 552bps to 49%** Prices of key raw materials were up 20% to 200% in FY22 on the non-availability of shipping containers, disrupting the global supply-chain and slashing the FY22 operating performance.

❑ **SRF and Fine Organic** maintained FY22 gross margins at 51.2% and 36.7% respectively (52.2% and 35.9% in FY21)




❑ **Navin maintained margins at 54.2%** The rising share in revenue of the high-margin business and better demand in the legacy business after the weak FY21 helped the company maintain its 54.2% gross margin, vs 54.4% in FY21.






Source:- Bloomberg

Gross margins of companies with greater exposure to crude oil severely contracted

Gross margin maintained where exposure to crude oil was low









Sharp margin contraction with more exposure to crude oil



Economics of scale not playing out in power and fuel costs






On analysing power and fuel cost, we find that the percentage change in power and fuel costs was much higher than the change in revenue. Vinati's revenue grew 69% in FY22 while its power and fuel cost rose 90%. Similarly, Atul's revenue grew 36% in FY22 and its increase in power and fuel cost was 65%. For only Fine Organic it was lower than revenue growth.



More exports resulted in more freight and forwarding expenses

As percent of sales, the average increase in freight and forwarding expenses was 99bps y/y to 3.3% due to challenges in shipping logistics, higher fuel costs and other issues. Further, the company whose business-mix change favored exports was faced with more challenges, resulting in higher freight and forwarding expenses.



- ❑ **Atul's** export mix increased to 50%, from 47% in FY21. Its freight and forwarding expenses rose to 5.2%, vs 2.5% in FY21.
- ❑ **Fine Organic's** export revenue share, too, grew to 60%, compared to 54% in FY21. Its freight and forwarding expenses rose 269bps y/y to 5.3%.
- ❑ **Deepak Nitrite's** export mix declined to 22%, vs 29% a year ago. Its freight and forwarding expenses declined to 2.4%, vs 3.1% a year ago.



Note:- Vinati not disclosed freight and forwarding expenses







Strong revenue growth helped better absorb employee costs and other expenses

- As percent of sales, employee costs declined an average 142bps y/y to 6.6% due to strong revenue growth and better absorption of cost through greater capacity utilisation. Only Navin's employee costs rose to 12.5% (of sales) as it added employees in technology and design, R&D and business development for coming expansions.
- To save operating margins from higher RM and utility costs, companies worked on operating efficiencies and controlled operating expenses. As percent of sales other expenses contracted an average 101bps to 6.4%. The most reduction was seen in Atul Ltd (down 174bps to 9.1%) followed by Deepak Nitrite (157bps y/y to 3.1%), Fine Organic (102bps y/y to 3.1%), Vinati Organics (97bps y/y to 7.2%) and SRF (79bps y/y to 6.4%). Navin's other expenses, however, remained flat to 9.6%.



Depreciation was ~6-8% of gross block







The average depreciation rate (as percent of gross block) for the past eight years was 7.1%. The FY22 depreciation rate (as percent of gross block) was 6.5% vs 6.9% in FY21. There was no major change in the rate for SRF, Vinati, Navin and Deepak and Atul. For Fine Organic, however, it declined substantially to 7.7% (vs 10.5% in FY21) as the company used the written-down method of depreciation and capex capitalisation was on a pro-rata basis. All other companies use the straight-line depreciation method.



Source:- Company

Strong revenue growth not translating to operating performance

- In the challenging business environment of FY22, chemicals companies' EBITDA margins contracted. Fine Organic improve its margin on the better absorption of employee cost, and higher gross margin, though partially hurt by higher operating expenses, mainly freight and forwarding expenses.
- Atul, Deepak Nitrite and Vinati's FY22 EBITDA margins contracted a severe 668bps, 503bps and 1,007bps to 17.9%, 23.6% and 26.9% respectively. Key reasons were lower gross margins, higher power & fuel expenses, utility and freight & forwarding expenses. The better absorption of employee costs on the good revenue partially supported their EBITDA margins. Navin's EBITDA margin contracted 181bps y/y to 24.4%, due to higher power & fuel and employee costs. SRF's EBITDA margin was retained at 25%, vs 25.4% a year ago.



Other income analysis

Particulars (Rs m)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remarks
SRF	30	52	50	39	45	151	90	240	Increase in short-term deposits (3 months) to Rs2bn, vs Rs1 m in FY21
% of Cash and Investments	1.5	0.9	1.9	1.8	1.5	4.7	1.3	3.1	
Vinati	39	49	33	76	61	95	21	140	Sharp rise on receiving interest on loans to Veeral Additives Pvt. Ltd.
% of Cash and Investments	13.0	6.4	4.9	5.6	6.1	3.4	0.7	14.3	
Fine Organic	2	12	10	5	17	80	68	61	No material change
% of Cash and Investments	6.6	2.9	5.7	3.7	1.5	3.8	2.6	2.6	
Navin	52	55	56	156	15	33	176	157	In absolute terms, no major change. Navin deployed FY21 cash to capex in FY22 due to which in percent terms increased substantially
% of Cash and Investments	4.2	2.6	2.3	3.9	0.4	0.8	2.8	7.9	
Deepak Nitrite	7	11	17	16	15	21	33	21	No material change in absolute terms; in percent, declined due to rise in short-term investment to Rs4.4bn (Rs1.9bn in FY21)
% of Cash and Investments	21.3	1.2	1.3	2.0	5.7	6.8	1.5	0.4	
Atul	28	99	124	153	118	253	745	238	~93% drop in dividend from equity investments, to Rs42m, vs Rs570m in FY21
% of Cash and Investments	0.7	2.7	2.8	3.0	1.5	2.2	4.5	1.9	

Note Other income includes only interest and dividend income.

Finance-cost analysis







Interest expenses	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remarks
SRF	1,376	1,305	1,018	1,239	1,984	2,007	1,340	1,159	Capitalisation of interest expenses
% of debt	5.6	5.2	4.2	3.9	5.3	4.9	3.9	3.2	
Vinati	98	79	19	12	9	11	2	3	Not material; Short-term loan, payable on demand, taken in H2 FY22
% of debt	14.9	18.6	80.4	8.0	25.6	315.2	10.5	1.4	
Fine Organic	77	83	44	32	18	48	61	51	No major change
% of debt	7.5	8.1	10.9	5.9	1.4	3.9	6.9	8.7	
Navin	33	38	27	12	8	20	18	19	Long-term Rs1bn loan to be used for capex, taken later in FY22 and not shown in Sep'21 B/S. Interest expenses not reflected in the P&L due to capitalisation
% of debt	5.4	7.3	14.6	9.4	20.0	8.8	7.3	1.6	
Deepak Nitrite	380	397	341	451	832	1,149	742	340	Declined as long-term debt, repaid (Rs1.9bn in FY22, Rs5.2bn in FY21)
% of debt	7.0	7.5	4.7	4.6	7.0	10.4	12.6	10.8	
Atul	257	275	252	127	74	94	94	92	Long-term debt repaid. Short-term working-capital loan taken in H2 FY22
% of debt	8.7	8.7	15.0	80.1	13.5	8.7	7.4	6.6	

Profit growth in FY22, lower than revenue growth


Profit growth (40% y/y) in the industry was lower than revenue growth (50% y/y) due to subdued operating performances.

- ❑ **SRF** Profit growth (58% y/y to Rs18.9bn) was higher than revenue growth (48% y/y to Rs124bn) as it had a Rs727m forex gain (Rs119m in FY21), maintained its EBITDA margin and reduced interest expenses (capitalising debt cost on capex), but was partially hurt by higher tax expenses. The net profit margin improved ~100bps to 15%.
- ❑ **Vinati** Profit growth (29% y/y to Rs3.5bn) was lower than revenue growth (69% y/y to Rs16bn) due to the lower gross margin (down 1,266bps y/y to 46.7%), a higher tax rate (22.8% vs 19.7% in FY21), but partially supported by higher other income (Rs137m interest income, including interest on inter-corporate deposits).
- ❑ **Fine Organic** PAT growth was exceptional, up 116% y/y to Rs1.2bn (revenue growth 66%) supported by the higher EBITDA margin (19.4% vs 17.6% in FY21), lower depreciation expenses down 15% y/y (diminishing-value method) and higher other income, up 93% y/y (on forex gains).
- ❑ **Navin Fluorine** Profit growth (9% y/y to Rs2.6bn) was lower than revenue growth (23% y/y to Rs14.5bn) due to the lower EBITDA margin as other expenses were high (mainly power & fuel cost), lower other income as it had Rs346m interest on an income-tax refund in FY21, just Rs53m in FY22, partially supported by a lower tax rate (23.6%, vs 31% in FY21)
- ❑ **Deepak nitrite** Profit was up 37% y/y to Rs10.6bn, against 56% revenue growth to Rs68bn, hurt by the lower gross margin (33.1%, vs 42% in FY21), higher depreciation expenses (gross block Rs25.7bn in FY22 vs Rs22.9bn in FY21), partially supported by higher other income (up 98% y/y) and lower interest expenses (down 54% y/y).
- ❑ **Atul** Despite 36% revenue growth, profit declined 8% y/y to Rs6bn, hurt by the lower gross margin (down 552bps y/y to 49.1%), higher depreciation (Rs5.6bn capex) and lower other income (drop in dividend and interest income).

Profit growth in FY22, lower than revenue growth




- ❑ Generally, chemicals companies are debt free. In FY15, their debt-equity ratio averaged 0.6x, declining to 0.1x in FY22 despite huge capex over the years. Atul, Vinati and Navin are completely debt-free.
- ❑ Deepak Nitrite has been repaying debt for the last three years. It repaid Rs2.8bn in FY22 as major capex was completed over FY16-18.
- ❑ SRF's short-term debt rose to Rs18bn (Rs14.4bn in FY21) while Navin took Rs1bn debt to fund capex for long-term contracts. Over FY15-FY21, Navin's annual debt averaged Rs280m against Rs10.4bn net worth.









Capex-to-OCF has been over 100% in the last eight years

- ❑ Indian chemicals companies have been in an expansion mode for the last few years to become major global suppliers and reduce dependence. China is dominant in the industry. The shift has been seen in more exports from India in the last few years after factories in China have closed due to pollution issues, the Covid-19 outbreak and environment concerns.
- ❑ The Indian companies are focusing on exports, aiming to address local demand for import-substituted products. Deepak Nitrite entered phenolics a few years back and now has a near 50% market share in India.
- ❑ On analyzing last eight years' data, it can be seen that companies have invested ~108% of operating cash-flow in capex. This was the highest for Deepak Nitrite (186%) followed by Navin (169%) and SRF (101%). Navin's operating cash-flow to capex ratio increased considerably in FY22 as it invested in many long-term contracts.
- ❑ We expect this trend to continue as the Indian chemicals sector in a sweet spot, and recent challenges in China and shift of supplies would support Indian companies.



Capex to OCF, over 100% in the last eight years



Source:- Company

❑ **Vinati Organics**

- Targeting Rs6bn capex in the next two years (ATBS expansion, new products in niche segments).
- On track to further expand niche portfolio of products that will enable import substitution.

❑ **Deepak Nitrite**

- Rs15bn capex, expected to be commissioned from FY23 in a phased manner in the next 1-2 years. Adding value-added products in phenol and acetone, adding chemistry platforms, investing in upstream and downstream projects. Working on new chemistries for expansion. Continuing to focus on launching value-added downstream products to substitute imports, primarily to capitalise on the more favourable demand situation.

❑ **Fine Organic**

- Capex amount not disclosed. In the process of acquiring land in Gujarat for greenfield expansion and focusing on expanding existing facilities for new and present product lines.

❑ **Navin Fluorine**

- Working on long-term contracts. Capex: Rs1.95bn in agro and pharma; Rs1.25 on agro-chemical fluoro-intermediates, Rs5.4bn to supply fluoro-specialty chemicals to capitalise in FY23 and FY24. R&D capabilities and deep fluorination expertise will continue to strengthen the newer-opportunities pipeline, while working on capacity expansion and enhancing its product portfolio in specialty chemicals. Aiming to explore overseas potassium fluoride demand. De-bottlenecking its hydrofluoric plants in FY23: Rs750m capex to de-bottleneck CGMP3. Further, it plans to set up a dedicated CGMP4 plant.

❑ **Atul**

- In an expansion phase to backward integrate by adding chlorine and caustic soda.

❑ **SRF**


- Many expansions in different business categories are ongoing; Intermediates for agrochemicals at Dahej (capex Rs1.15bn), pharma products (capex Rs1.9bn) in the chemicals business, an aluminium-foil manufacturing facility in packaging films, capex Rs4.25bn; and many more.

Cash-conversion cycle stretched due to fewer payable days


- ❑ Due to uncertain market conditions, supply-side issues, container unavailability and logistics issues, chemicals companies largely focused on maintaining higher stocks to supply customers timely. All companies' (except Vinati) cash-conversion cycles in FY22 lengthened on average by ~16 days mainly due to drops in payable days due to higher raw-material costs. Further, we believe that companies paid creditors earlier for better terms and timely supplies. Vinati was the exception. Its cash-conversion cycle shortened to 130 days (vs 158 in FY21) chiefly due to fewer inventory days. The companies' receivables days were maintainable because of their focus on efficient collection.
- ❑ SRF's cash-conversion cycle lengthened to 55 days vs 45 days in FY21 due to early payments to creditors (126 days in FY22 vs 144 in FY21).
- ❑ Vinati's cash-conversion cycle shortened to 130 days (from 158 in FY21 due to fewer inventory days (75 in FY22, vs 115 in FY21) partially hurt by fewer payable days (49 in FY22, vs 63 in FY21).
- ❑ Fine Organic's cash-conversion cycle lengthened 17 days to 84 days due to more inventory days (72, vs 63 in FY21) and receivables days (59, vs 52 in FY21).
- ❑ Deepak Nitrite's payable days declined substantially by 25 days, to 45. Further, its inventory days shortened by 10 days, to 52. Management says revenue growth and efficient inventory operations led to faster stock churning, which resulted in fewer inventory days
- ❑ Atul's cash-conversion cycle lengthened to 103 days (from 78 in FY21) chiefly due to a huge reduction in payables days (down 32, to 89). Receivables days were the similar (71, vs 72 in FY21) and inventory days declined to 122 (128 in FY21).
- ❑ Navin's cash-conversion cycle lengthened to 151 days (from 137 in FY21) chiefly due to more inventory days (up 19 to 141). Its payables days were 80, vs 73 in FY21.

Cash-conversion cycle lengthened due to fewer payable days


Receivable Days




Inventory Days



Payable Days




Cash Conversion Cycle




- ❑ After analyzing inventory break-ups, we find that companies maintained more raw-material stocks in FY22 than in previous years. Disruption in imports and logistics-related challenges impelled companies to focused more on maintaining high stocks to run production smoothly and serve customers on time.
- **Fine Organic** was the major beneficiary. It gained more business and market since it maintained higher raw-material stocks, which helped serve customers timely while competitors shuttered plants due to non-available raw materials. It maintained 48% of raw-material stocks (40% in FY21) to counter supply constraints (bans by Indonesia and Malaysia) and logistic challenges.
- **Navin Fluorine.** Raw material stocks as percent of total stocks rose to 53% (from 40% in FY21) and averaged 36% over FY15-21. (~68% of raw material required is imported as per past data (FY11-FY17)
- **Vinati Organics.** Raw material stocks increased to 36% of total stocks (from 27% in FY21) and averaged 29% over FY15-FY21.
- Companies such as Atul, Deepak Nitrite and SRF did not maintain high raw-material stocks.


RM inventory share increased in total inventory




FG inventory share remained same in total




WIP inventory share remained same in total



Stores & Spares share declined in total inventory



Stock-in-trade share in total inventory



Provision for doubtful debts ~0.5-1.3% of receivables

SRF	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables	6,107	5,145	6,569	6,807	10,288	8,911	12,746	17,925	SRF's provision for doubtful debts fell substantially to an average of 0.3% over FY19-22, against a 2.4% average over FY15-18.
Allowance for Expected Credit Loss	103	172	152	158	25	36	50	35	
% of Receivables	1.7	3.3	2.3	2.3	0.2	0.4	0.4	0.2	

Vinati	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables		1,148	1,405	1,771	2,440	2,018	2,772	4,584	In the past, Vinati made no allowance for bad and doubt full debts. In FY22, it made a Rs11 m provision for this, 0.2% of receivables
Allowance for Expected Credit Loss		NA	NA	NA	NA	NA	NA	11	
% of Receivables		0.0	0.0	0.0	0.0	0.0	0.0	0.2	

Fine Organic	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables			1,104	1,458	1,556	1,323	1,616	3,014	Fine Organic averaged 1.1% of total receivables charged as allowances for expected credit risk. It was the highest 1.8% in FY17 declining to 0.3% in FY22.
Allowance for Expected Credit Loss			20	21	12	16	14	10	
% of Receivables			1.8	1.4	0.8	1.2	0.8	0.3	

Provision for doubtful debts ~0.5-1.3% of receivables


Navin Fluorine	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables	1,199	1,519	1,376	1,556	1,727	2,185	2,841	3,577	Navin's provision for bad and doubtful debts was less than 1% of receivables. It was 0.7% over the last eight years. In FY22, it was 0.6% vs 0.7% a year ago
Allowance for Expected Credit Loss	3	9	8	14	13	19	20	21	
% of Receivables	0.2	0.6	0.6	0.9	0.8	0.9	0.7	0.6	

Deepak Nitrite	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables	3,110	3,125	3,603	4,118	5,750	6,127	7,563	11,291	Deepak Nitrite's provision for bad and doubtful debts has been constantly increasing in the last eight years. It was 0.7% of receivables in FY15, increasing to 4.2% in FY21 and 3.2% in FY22.
Allowance for Expected Credit Loss	23	44	33	66	72	146	315	359	
% of Receivables	0.7	1.4	0.9	1.6	1.3	2.4	4.2	3.2	

Atul	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	
Particulars	(Rs m)								Remark
Receivables	4,392	4,414	5,190	7,234	6,985	7,197	7,332	9,890	Atul's provision for bad and doubtful debts increased in the last four years to average 1.4% of receivables. It was ~0.6% over FY15-18.
Allowance for Expected Credit Loss	27	38	32	26	76	103	122	127	
% of Receivables	0.6	0.9	0.6	0.4	1.1	1.4	1.7	1.3	


OCF declined ~40% y/y due to higher working capital

- On analysis of operating cash-flows, all companies' OCF declined ~40% y/y due to more working capital invested and subdued operating performances on higher raw material, power, fuel, utility and logistic expenses. SRF, however, increased its OCF due to better working-capital management and a sustainable operating performance
- Over FY15-FY22, chemicals companies' average capex-to-OCF was 108%, the highest for Deepak Nitrite (186%; major Rs11bn capex for the phenol and acetone plant over FY17-19) and 101% for SRF (the last eight years' annual average capex of Rs10bn). Navin did an average Rs800m capex yearly over FY15-FY21, which rose substantially in FY22 as it invested Rs5.8bn on long-term contracts. Similarly, Atul's average capex-to-OCF was 55% over FY15-FY21 (average annual capex of Rs2.6bn), which rose a substantial 255% in FY22 (capex Rs5.9bn). Management talked of Rs15bn capex in the next 2-3 years on products, backward integration and expansion. All chemicals companies generated positive FCF in FY22, except Atul, Vinati and Navin as clarified above.
- The chemicals companies generally have investments (current and non-current, MFs, securities). To fund working capital and capex, Atul and Navin sold their investments of Rs4bn and Rs3.8bn respectively in FY22. Deepak Nitrite spent Rs2.4bn on current investments (MFs) as capex was low and it targeted major capex on downstream products in the next two years.



FCF generated despite huge capex

- Over the last eight years, chemicals companies expanded their gross block 2.9x, Atul the most (4.6x), followed by Deepak Nitrite (3.1x) and Fine Organic (2.9x). Over FY15-21, Atul generated free cash-flow averaging Rs2.4bn. Its FCF was negative in FY22 as OCF declined due to higher working capital and capex of Rs5.9bn.
- Deepak Nitrite** generated positive FCF in the last few years except FY17-19 as it added phenol and acetone capacity (greenfield expansions).
- Over the last eight years, **Fine Organic** generated positive free cash-flows on average annual capex of Rs548m. It is coming up with greenfield capex in Gujarat for future expansions to cater to growing opportunities.
- Vinati's** FCF was negative only in FY22 due to higher capex of Rs1.6bn against its annual average capex of Rs0.9bn over FY15-21. Further, higher working capital hurt OCF in FY22.
- Despite investing Rs30bn capex in the last two years, **SRF** generated positive FCF on the back of its strong operating performance and better working-capital management. Due to huge capex of Rs5.8bn in FY22, **Navin** reported negative FCF of Rs5bn due to higher working capital.




Cash, bank and investment at 16% of capital employed







In FY15, the chemicals companies maintained 9% of capital employed in cash, bank and investments. This was the highest for Navin and Atul as capex was low. Despite strong capex in the last 3-4 years, this percentage improved, coming at 24% in FY21 (from 15% in FY18) supported by strong profitability. In FY22, it declined to 14% due to lower profits, higher capex and working capital investments.

- ❑ **Deepak Nitrite** Cash, bank and investments as percent of capital employed was just 0.5% in FY15, rising to 13% in FY22 on the strong execution of the phenol/ acetone project and a 54% CAGR in profits.
- ❑ **Navin** has a strong balance sheet. Its cash, bank and investments as percent of capital employed averaged 30% over FY15-FY22, plunging steeply to 11% in FY22, the lowest in the last eight years as it invested Rs5bn on capex, largely funded by internal accruals.
- ❑ **Atul's** cash, bank and investment as percent of capital employed averaged 26% over FY15-FY22. It was the highest (40%) in FY21 and dropped to 27% due to funding capex of Rs5.9bn via internal accruals and to lower profit .
- ❑ **Fine Organic's** cash, bank and investments as percent of capital employed improved to 32% in FY21 against only 1% in FY15. In FY22, it declined 23% due to higher working capital.
- ❑ **SRF** is in the capex mode over last few years. Its gross block rose 2.5x in FY22 over FY16. Its cash, bank and investments as percent of capital employed averaged 5% over FY15-FY22 and 6% in FY22.
- ❑ **Vinati's** cash, bank and investments as percent of capital employed averaged 12% over FY15-FY22. It declined to 5% in FY22 due to higher capex and working capital.

Cash, bank and investments as % of capital employed




Cash, bank and investment: 16% of capital employed



R&D continued to be focused on

- ❑ Indian chemicals companies are investing more on R&D to develop their niche in the market. They are also trying to develop “green” products and chemistries.
- ❑ Navin invested 2.4% of annual revenue in R&D (capital + recurring) in FY22. Its R&D spend averaged 2.2% over FY15-22. SRF’s averaged 1.7% (0.9% in FY22). Compared to them, Fine Organic, Deepak Nitrite and Atul are investing an average ~0.4-1% of annual sales on R&D. Of the six companies, R&D spend averaged an 12% CAGR over FY15-FY22 to Rs2.1bn, compared to Rs1bn in FY15.
- **Navin Fluorine** invested in cutting-edge R&D, graduating towards sectoral leadership. A deep research-based culture translated to timely development of products cum grades, superior customer value, high product quality and robust product characteristics.
- **SRF.** Over two decades, Chemical technology dedicated for R&D group enabled growth in fluorinated molecules. Now it is increasingly engaged in developing complex non-fluorinated intermediates. This is crucial to keep enhancing CTG’s capabilities and support systems with rising complexity in developing products and reducing timelines for delivery to market.
- **Vinati.** R&D on new projects and new products are strong business drivers for Vinati. It is focusing on expanding capacities and strengthening its R&D pipeline with better synergies to take advantage of growing opportunities in global markets. On average, the R&D team is working on developing of 10-12 products, most of them niche with unique chemistries.
- **Fine Organic.** Focusing on R&D and innovation capabilities. FINE’s green additives have been effectively replacing potentially hazardous chemicals in a wide range of industries such as plastics, packaging, foods, cosmetics, rubbers and coatings, without compromising on performance.
- **Atul.** Focused R&D efforts on process improvement of existing products, recovery of products from waste, and developing products and formulations. The company increased yield of six products, decreased consumption of raw materials and solvents in eight products, recovered two value-added products from waste and introduced 24 products in the market.
- **Deepak Nitrite** is making sizeable investments in R&D to build in-house ability to create a pipeline of products for future growth. Its R&D centre has filed applications for 36 patents cumulatively and develops innovative and advanced intermediates that drive portfolio expansion.



Note: Vinati not disclose its R&D spent

SRF's Aspirations 2030 emphasizes the company's commitment to innovation. The company is engaged in the development of complex non-fluorinated intermediates.

Navin

Expected to invest Rs400m in upgrading R&D and pilot facilities.

Added new molecules, broad-bases the portfolio and created a strong foundation.

Navin engaged industry- and subject-matter experts to enhance specialisation.

Fine Organic

New R&D centre in Dombivli

Vinati Organic

R&D in the relevant areas of business operations will continue.

Emphasis will be on adopting products and processes to improve performance, be more environmental friendly to meet customer needs.

Atul

Investing in people and equipment to strengthen its R&D and thereby enhance its capabilities.

Deepak Nitrite

Making sizeable investment in R&D to build in-house capability to create a pipeline of products that will drive future growth.

- ❑ **Fine Organic** pays the highest share of profit to its directors and KMP compared to other companies.
 - It gave ~14.7% of profit as remuneration in the last six years and 6.7% in FY22 vs 12% in FY21.
- ❑ **Deepak Nitrite** paid an average 10.8% of profit as remuneration to directors and KMP in the last eight years.
 - For the last three years this figure has been declining regularly. It was 4.2% in FY20, declined to 2.1% in FY21 and then to 1.6% in FY22.
- ❑ **Navin's** average payment to directors and KMP as percent of PAT was 8.4%.
 - This was the highest in FY15 at 9.2%, falling to 6.3% in FY22.
- ❑ **SRF** paid an average 4.8% of profit as remuneration to directors and KMP in the last eight years.
 - It consistently decreased from 6.3% in FY15 to 3.1% in FY22
- ❑ **Atul's** payment to directors and KMPs was 3.4% in FY22, vs an average 3.6% over the last eight years.
- ❑ **Vinati Organics** paid an average 2.2% of profit as remuneration to directors and KMP in the last eight years.
 - It was ~2.7% average over FY15-FY19, which declined to average 1.7% over FY19-FY22.

Remuneration to directors, KMP

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Vinati		(Rs m)							
Vinod Saraf	Chairman	9.5	10.5	11.5	12.6	13.9	15.2	16.7	18.4
Vinati Saraf Mutreja	Managing Director and CEO	7.2	8.0	8.7	9.6	10.5	11.5	12.6	13.7
Jayesh Ashar	COO	5.0	5.9	6.8	7.4	8.3	9.2	10.3	7.8
Viral Saraf Mittal	Director, CSR	4.1	4.5	4.9	5.4	5.9	6.5	7.1	11.7
N. K. Goyal	CFO	4.3	4.9	5.6	5.8	6.4	7.2	7.9	9.1
Total Remuneration		30.1	33.7	37.5	40.8	45.0	49.6	54.6	60.7
Profit after tax		1,158	1,316	1,403	1,439	2,825	3,338	2,693	3,466
Remuneration, % of PAT		2.6	2.6	2.7	2.8	1.6	1.5	2.0	1.8

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Fine Organic		(Rs m)							
Prakash Damodar Kamat	Chairman			74.2	23.7	22.8	26.4	28.8	35.0
Mukesh Maganlal Shah	Managing Director			60.7	25.6	22.8	26.4	28.8	35.0
Jayen Ramesh Shah	Executive Director & CEO			74.2	23.7	22.8	26.4	28.8	35.0
Tushar Ramesh Shah	Executive Director & CFO			74.2	23.7	22.8	26.4	28.8	35.0
Bimal Mukesh Shah	Executive Director			33.3	19.3	22.8	26.4	28.8	35.0
Total Remuneration				316.7	116.0	114.0	132.0	144.0	175.0
Profit after tax				779	953	1,362	1,648	1,203	2,596
Remuneration, % of PAT				40.7	12.2	8.4	8.0	12.0	6.7

Remuneration to directors, KMP

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Navin		(Rs m)							
Vishad P. Mafatlal	Chairman wef Aug'16	0.7	0.9	26.9	56.5	58.8	68.4	86.2	90.8
Hrishikesh A. Mafatlal	Chairman up to Aug'16	16.7	24.7	23.6					
Shekhar S. Khanolkar	MD up to Oct'18	20.0	28.1	34.7	66.0	45.3			
Radhesh R. Welling	MD wef Dec'18				-	16.8	54.2	71.7	74.6
Atul K. Srivastava	Director up to Apr'15	12.9	16.4						
Sitendu Nagchaudhuri	CFO up to Jun'18		7.0	12.6	14.7	5.8			
Ketan Sablok	CFO wef Jun'18					7.6	10.6	NA	NA
Basant Kumar Bansal	CFO wef Nov'21							NA	NA
Total Remuneration		50.2	77.0	97.8	137.3	134.4	133.3	157.8	165.4
Profit after tax (Adj.)		546	835	1,366	1,659	1,491	1,800	2,420	2,631
Remuneration, % of PAT		9.2	9.2	7.2	8.3	9.0	7.4	6.5	6.3

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Deepak Nitrite		(Rs m)							
Deepak C. Mehta	Chairman & MD	26.8	34.3	33.2	50.6	90.7	139.2	69.4	69.9
Ajay C Mehta	MD up to Dec'17	24.8	33.7	9.8	7.3	-	-	-	-
Maulik D. Mehta	ED & CEO wef Jun'20			7.5	10.3	17.1	15.3	26.0	32.9
Meghav D Mehta*	Executive Director	1.2	2.6	3.0	5.4	5.5	8.2	15.4	19.5
Sanjay Upadhyay	CFO	12.6	14.6	16.3	20.6	29.4	31.3	35.9	43.2
Umesh Asaikar	CEO up to May'20	30.0	36.8	38.8	47.1	58.9	64.7	12.9	-
Total Remuneration		95.4	121.9	108.6	141.2	201.6	258.7	159.6	165.5
Profit after tax (Adj.)		529	627	963	790	1,737	6,110	7,758	10,666
Remuneration, % of PAT		18.1	19.4	11.3	17.9	11.6	4.2	2.1	1.6

* Payment for services rendered over FY15-FY20







Remuneration to directors, KMP

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
SRF									(Rs m)
Arun Bharat Ram	Chairman	44.8	46.3	48.4	50.4	55.3	58.3	76.1	127.6
Ashish Bharat Ram	MD	37.6	41.0	47.7	51.1	59.1	69.4	93.8	127.6
Kartik Bharat Ram	Joint MD	36.0	38.1	47.3	50.3	58.4	68.5	92.1	124.8
Anurag Jain	President & CEO (Specialty Chemicals and CTG)	11.8	15.0	18.7	22.8	60.2	40.9	44.5	56.1
Prashant Yadav	President & CEO (Fluorochemicals and Technical Textile)	11.6	15.0	18.6	22.5	59.8	40.4	44.0	56.6
Prashant Mehra	President & CEO (Packaging Films, CF & LF)	11.8	15.0	18.7	22.6	60.1	41.6	45.2	56.8
Sanjay Chatrath	President and CEO – TTB(wef Oct'17)				14.1	18.8	25.2	27.6	24.3
Sushil Kapoor	President & CEO (Technical Textiles) (up to Sep'17)	21.3	23.3	24.9	19.3				
Rajendra Prasad	CFO up to Mar'16	15.9	17.8						
Anoop k Joshi	CFO up to Mar'19		11.2	16.2	16.5	21.8			
Rahul Jain	CFO wef Apr'19						17.2	17.6	21.2
Total Remuneration		190.7	225.3	240.5	269.6	393.5	361.5	440.9	595.0
Profit after tax		3,028	4,299	5,150	4,617	6,416	10,191	11,979	18,889
Remuneration, % of PAT		6.3	5.2	4.7	5.8	6.1	3.5	3.7	3.1

Remuneration to directors, KMP

Name	Designation	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Atul		(Rs m)							
S S Lalbhai	Chairman & MD	49.8	65.6	70.7	70.4	100.9	120.4	140.0	136.2
S A Lalbhai	MD	17.4	20.6	22.6	22.6	24.9	26.9	27.7	29.8
B N Mohanan	Whole-time Director and President – Utility and services	8.6	10.5	11.8	11.1	13.0	15.3	15.5	18.4
S R Nammalvar	Whole-time Director	4.8							
T R Gopi Kannan	Whole-time Director and CFO	4.7	14.1	14.6	13.9	16.3	21.1	19.8	21.6
Total Remuneration		85.2	110.8	119.7	118.1	155.1	183.8	203.1	206.0
Profit after tax		2,407	2,742	3,230	2,765	4,322	6,665	6,571	6,043
Remuneration, % of PAT		3.5	4.0	3.7	4.3	3.6	2.8	3.1	3.4

Remuneration to directors, KMP



Navin's MDA

Key highlights

The Indian Specialty Chemicals sector would double by 2025

- ❑ The Indian specialty chemicals sector was \$32bn in 2020, registering an 11.7% CAGR over CY15-20.
- ❑ By 2025, it is expected to double to \$64bn, recording a 12.4% CAGR over CY20-25, attributed to global players focusing on India as an alternative to China, where the government is tightening regulatory controls due to environmental hazards

11% CAGR in electronic appliances

The Indian electronic appliances sub-segment is expected to reach \$21.2bn in 2025, an 11% CAGR over 2019-2025. A/C production is expected at 16.5m units in FY25, from 6.5m in FY19. Refrigerator production is expected to increase from 4.5m units in FY19 to 27.5m in FY25.

Rising income levels

India's per-capita income is expected to be ~\$1,850 in 2022 and \$1,920 in 2023. This could heighten discretionary spending

Focus on R&D

Growing investments in R&D have enhanced the production value-chain. Further, offering R&D capabilities as a part of contract research and manufacturing services, could enhance margins.

Domestic availability

India imports most petro-chemical intermediates. Mounting demand by specialty chemicals companies has led to petro-chemicals companies manufacturing petro-chemical intermediates through the diversion of ethylene and propylene.

Reducing dependence on China

Most global manufacturers depended on China's for specialty chemicals. However, they are now seeking alternative sources of supply due to growing Chinese government controls on the production of environmentally hazardous chemicals. This could widen the market for India

Fluorination emerging as key chemistry in pharma and agro industries

- ❑ The global fluoro-chemicals sub-segment is expected to register a 5.2% CAGR to \$25.1bn between now and 2026. Fluorinated organic compounds are of interest in the pharmaceutical and agrochemical sectors. The application of fluoro organic compounds can be attributed to the unique metabolic stability, lipophilicity and binding affinity offered by them.
- ❑ The global fluoro-elastomer market is valued at \$1.8bn by 2027, growing at a CAGR of 3.7% (2020-27), driven by increasing use of sealing applications. The global fluoro-carbon chemicals market is expected to grow at 7.4% CAGR between 2021 and 2027, owing to the growing demand for electronic appliances.
- ❑ The market size of the therapies in which fluorine is used is expected to clock a 5% CAGR, from \$423bn in CY20 to \$535bn in CY25.

25%

The percentage of fluorine-containing drugs approved by the FDA over the last five years

67%

The percentage of fluorine containing pesticides over the last five years

22%

The percentage of drugs approved by the FDA containing at least one fluorine atom on average over the last two decades

53%

The percentage of pesticides introduced during 1998-2020 containing fluorine atoms

The Indian fluoro-chemicals sub-segment

- ❑ Fluoro-chemicals are an essential ingredient in a number of sectors such as agrochemicals, dyeing, automotives and electronics, among others. Demand growth in any of these could strengthen demand for fluorochemicals.
- ❑ In 2020, around a third of India was living in cities. By 2031, 3/4th of India's national income could come from cities, heightening demand for better infrastructure and electronic appliances, strengthening in turn the market for fluorochemicals.

Agro-chemicals

Being agriculture-dominant (more than 50% of India's population depends on agriculture), demand for fertilizers and insecticides is swelling.

India is the fourth-largest agrochemicals market, creating a vast base for fluorochemicals offtake.

Dyeing

India addresses 16% of global demand for dyestuffs and dye intermediates. The India colourants segment has a ~16% worldwide market share.

Pharma

India is the third-largest pharmaceutical market by volume. The Indian pharmaceutical sector was expected to grow between 9 and 11% during FY22 due to domestic demand.

Automobile

India is projected to emerge as the world's third-largest automobile market by volume by 2026, driven by population growth.

Electronics

The Indian electronics market is expected to grow from \$72bn to \$300bn by 2025, following wider acceptance of electronics and digitisation following the pandemic.

Navin Fluorine – Outlook for each category

- Navin is enthused about the quality and quantum of growth opportunities in the pipeline that would translate to profitable growth in the foreseeable future. It is focusing on three value chains and building blocks, of which two are scaling up well. It identified two building blocks of substances that it expects to grow. These building blocks offer opportunities in its own critical value-chains, offering customers clear risk mitigation. Navin is working on new chemistry and engineering technologies which can be widely applied across businesses, reinforcing its technology leadership.

Specialty Chemicals

Developing a product on the fluoropyridine platform. Expected to emerge as the first such producer in India. Launch by end-2023

~20% revenue growth in FY23, catalyzed by its new Dahej site commissioned in Jul'22

CRAMS

Intends to invest in advanced systems and processes to facilitate expansion.

Aspires to strengthen project management and technical capabilities.

CRAMS business expected to grow ~25% in FY23

Refrigerants

Engaged in getting its R22PTFE samples approved, following which a large market could emerge from buyers solely dependent on China.

Inorganic Fluorides

Seeks to explore potassium fluoride demand from overseas and de-bottleneck its hydrofluoric plants in FY23.

Widen its customer profile especially from the solar and steel segments.

Navin Fluorine Advanced Sciences (subsidiary)

New process plant at Dahej expected to be commissioned in FY23

MPP at Dahej for fluoro specialty products is ongoing

Expects attractive revenue growth and a higher margin arising from the expansion, strengthening business viability.

Vinati's MDA

Key highlights

- ❑ Specialty chemicals are particular products which provide a wide variety of effects and which many other industry sectors rely on.
- ❑ They are low-volume high-value products used across a number of consumer-facing industries. They can be some kind of formulation or single chemical entities whose chemical composition influences the end-product. Most specialty chemical formulations are patented and not easily replicable, which give them better pricing and higher yields.

The Global Chemicals Sector

\$5,027bn, with China accounting for a 39% market share, the EU 15%, with the US following with 13%.

India had a 4% market share in the world's chemicals market in CY20.

The global chemicals sector would touch \$6,780bn in CY25, a 6.2% CAGR

Global Chemicals Production

6.1% growth in 2021, To grow 3.5% in 2022, slower than in 2021, but still above average pre-Covid'19 levels.

In advanced economies, growth would be 3.1%, down from 3.9% in 2021.

Growth in emerging markets is expected to slow at a much stronger rate (2022: 3.7%; 2021: 7.2%).

The Indian Chemicals Sector

Market value of \$178bn in 2019 and to be \$304bn in 2025 at a 9.3% CAGR

Expected to draw investments of around Rs8tn by 2025

Sanctions on China support India

The US will reportedly impose export and investment sanctions against more Chinese businesses, including bio-technology, health-care and IT, per international reports.

As MNCs seek an alternative to China to avoid supply disruptions, India's chemicals sector stands in good stead.

Opportunities and challenges in the Indian specialty chemicals sub-segment

- ❑ The Indian specialty chemicals industry is expected to grow from ~\$40bn in FY20 to ~\$60bn in FY23, registering a 13% CAGR, outpacing the global average growth of ~5% CAGR
- ❑ The industry is also anticipated to gain in the medium term from potential changes in the global supply chain as major chemical producers strive to reduce their reliance on China. Indian companies are well positioned to benefit from this opportunity. The medium to long-term outlook is favourable for the industry supported by robust demand across end-user industries led by rising domestic consumption, strong export growth and rising import.

Opportunities

China +1

Greater reliance on a single manufacturing source, higher costs in China and intensifying US-China competition, stringent environment regulations and compliance expenses have led to firms diversifying supply chains outside of China.

Opportunities

Distributed manufacturing systems

To shift manufacturing from a single-country dominant set-up to a multi-country operation is a means to reduce risks associated with international supply-chain interruptions and political headwinds.

It represents a viable future path with international ambitions for domestic companies.

Opportunities

More use of technology

Rising use of technology and data analytics to improve margins will benefit the sector and key manufacturers.

Per a McKinsey report, chemicals companies will see a 3-5% increase in earnings from using Industry 4.0 technologies.

Opportunities

PLI schemes and a greater focus on R&D

More production-linked incentive (PLI) schemes in the chemicals sector

R&D is of utmost importance in this sector.

The government realised the importance of R&D and came up with a National Chemicals Policy that will strive to streamline and promote R&D within the sector.

Challenges

Dependence for RMs

35% of the RMs needed by Indian chemicals firms are procured from outside India.

Further, the companies which produce pharma intermediates have been obtaining RMs mainly from China.

Procurement risk considering the current global situation on account of disruptions worldwide.

Vinati's core strengths. Outlook for FY23

- Vinati has grown from a single-product manufacturer to an integrated operator. Its two state-of-the-art manufacturing units in Maharashtra now provide diverse innovative solutions to more than 35 countries and to some of the largest industrial and chemicals companies across the US, Europe and Asia.

Research

Focus on R&D and insight into complex chemistries has enabled it to improve productivity and efficiency of operations.

Market Leadership

Global leadership in IBB and ATBS
Domestic leadership in butyl phenols, IB and HPMTBE, making it a market leader in the industrial categories it serves.

Product Range with Synergies

Consists of niche products with integration and synergies in operating facilities.

Great emphasis on synergistic integration which has augmented its quest for global leadership and retain its competitive advantage.

Strong Collaborations

Well-founded technical partnerships with renowned national and global manufacturers.

Outlook

Strong volumes seen in Q4 FY22 are expected to continue in FY23 as well.

Expect all key products to do well and contribute to overall revenue growth in FY23.

Deepak Nitrite's MDA

Key highlights

The Global and Indian Chemical Industry

- ❑ Commodity' chemicals constitute ~80% of the global chemical industry, 20% being 'specialty' chemicals
- ❑ In terms of trade, globally ~25% of specialty chemicals are exported. China is the largest exporter, ~18% of exports

Shift in global chemical manufacture

In the past few decades, chemical manufacturing has shifted from the EU and North America to Asia, particularly China.

China's share of specialty chemical manufacturing grew manifold in the last 2 decades (6% in 2000)

APAC is likely to continue to grow comparatively rapidly, at a 7-8% CAGR over 2019-24, led by China and India

Strong demand to continue

Strong demand for both commodity and specialty chemicals should keep prices robust in FY22.

The industry will also experience increased capex as leading manufacturers focus on building capacities organically and inorganically.

Margin pressure to persist

Pressure on margins would persist amid higher raw material costs across the value chain.

Indian Chemical industry

Indian chemicals market would be \$304bn in FY25 at 9.3% CAGR (\$213bn in FY21)

Specialty chemicals constitute 22% of chemicals and petrochemicals in India.

Demand for Spechem is expected to clock a 12% CAGR over 2019-22 (vs. 11% FY15-21)

Indian Petro & Agro Industries


Expected to register a 7.5% CAGR over 2019-2023, with polymer demand rising 8%.

The Indian agrochemicals market is expected to record an 8% CAGR to \$3.7bn by FY22 and \$4.7bn by FY25.

In Oct'21, export of organic and inorganic chemicals rose 42% y/y to \$2.56bn

Focus on reducing imports of chemicals

- ❑ In the past two decades, the world has seen the rise of China as a major supplier of chemicals. Its proportion of production of global chemicals increased from a mere 6% in 2000 to ~25% in 2020.
- ❑ China's cost-competitiveness has recently contracted as a result of rising environmental costs and shrinking government subsidies
- ❑ China's carbon-neutral commitment target by 2060 is a major reason for its stringent environmental norms and tightening financing options for polluter companies. Subsequently, its industry is faced with structural headwinds, hurting global supply chains. These factors have increasingly compelled global majors to re-consider Chinese supplies. That is why they are building alternative sources, benefitting Indian chemicals manufacturers who are making huge investments in R&D, the environment, health and safety protocols. Besides, cost-competitive manufacturing and adequate technical knowledge make India an apt choice for global majors.
- ❑ The government of India is focused on improving the chemical sector's competitiveness and share of manufacturing in the overall economy.
- ❑ The FY33-34 vision for the chemicals and petrochemicals sector emphasizes ways to enhance domestic output, reduce import dependence and promote investment. It also overhauls the Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR) policy to encourage investment of Rs20trn by FY34-35. All this is likely to substantially reduce India's import dependence of basic RMs from neighbouring countries, including China.



Source:- Deepak Nitrite- Annual Report FY22

Structural growth drivers for the Indian chemicals sector

- ❑ End-use sectors (agriculture, consumer and retail, infrastructure, auto and electronics, and healthcare) could drive ~50% of added demand in chemicals. Besides, low labor costs, lower capex required (than developed countries) for capacity expansion, and supportive government policies would be additional levers of growth. Moreover, the government identifies the chemicals sector as a key growth driver, anticipated to account for 25% of GDP in manufacturing by 2025.
- ❑ The Union Budget 2022-23, allocated Rs2.1bn (\$27.43m) to The Department of Chemicals and Petrochemicals.

Shift in customer preferences

Rising demand for environmentally-friendly and socially-responsible products and services.

Moreover, becoming conscious of health and hygiene and demanding greener and safer products.

Increasing middle class and working population

By 2025, India's working population is expected to increase 33% to 1.14 billion along with tripled income levels.

The median age of the country would be 37 years by 2050.

Increasing adoption of specialty products

Growing health and hygiene awareness has resulted in greater adoption of nutra-ceutical ingredients such as vitamins, amino acids and so on, as well as personal- and home-care ingredients such as emollients, surfactants, active ingredients and so on.

Increasing adoption of specialty products

With rapid urbanisation and industrialisation, demand for engineering plastics and high-performance materials is increasing, driven by growth in automotive, electronics, consumer goods, construction, and other sectors.

Increasing adoption of specialty products

With increased demand for personal and public place dis-infestation following Covid19, the chloro-alkali, ethanol, personal care, and surfactant segments are expected to grow considerably in the near future.

Structural growth drivers for the Indian chemicals sector

- Furthermore, as global conglomerates look to de-risk their China-reliant supply chains, India's chemicals sector has the potential for enormous expansion. Moreover, to prevent dumping of chemicals in the country, the government has initiated several actions, including ADD, mandating BIS-like certification for imported chemicals, etc. It has also established a 2034 vision for the chemicals and petrochemicals sectors to explore opportunities to enhance domestic production, reduce imports and encourage investment in the sector. The intention is to establish an end-to-end manufacturing ecosystem through a cluster-development approach across the country.

Energy efficiency

The government of India is prioritising energy affordability.

Continued energy-efficiency measures are leading to the rise in demand for plastic insulation: polystyrene and polyurethanes, low thermal conductivity and light-weight polycarbonates, etc.

Increasing per-capita consumption

Current per-capita consumption of chemical products in India is about one-tenth the global average, expected to double by 2025.

Digitisation and Industry 4.0

Chemicals companies are implementing digitisation initiatives and tools in their supply chains, demand planning and pricing strategies.

Increasing M&A and investment-related activity

Downstream value-added opportunities, healthy demand for spechem and re-alignment of portfolios are key drivers of strong M&A and investments.

Global companies are looking at downstream opportunities in India and other high-growth economies. Saudi Aramco and BASF are showing interest in the Indian chemicals sector

Innovation and sustainability

Chemicals companies are incorporating sustainability and green-chemistry initiatives by constantly innovating products, technologies and processes, while closely working with customers and suppliers across the value chains.

- ❑ Vast potential for strong growth exists in the Indian economy. GDP is likely to double to \$5trn in the next decade, creating huge opportunities for Indian chemicals companies.

Better lifestyles

Rising disposable incomes, population median age, urbanisation and deeper penetration and demand in rural markets

More demand in Asia

Transition of consumption and production to Asian and southeast Asian countries in several industries, resulting in increased demand for chemicals and petrochemicals

Greater awareness

Consumer preferences moving toward healthy lifestyles and eco-friendly products.

Rising domestic demand

By 2023, there is an opportunity to manufacture \$111bn worth of chemical products for domestic application

Government initiatives

Under the AtmaNirbhar Bharat Abhiyaan, a production-linked incentive scheme has been introduced in the chemicals sector to increase domestic manufacturing and export of various chemicals

The benefit of prices passed on visible in FY23

- ❑ Recently, the effects of the Russia-Ukraine war are being felt across economies. Prices of every commodity, from oil to wheat to chemicals, are increasing due to congested supply-chain networks.
- ❑ Covid-19 spurred higher logistics and freight costs, as well as shutdowns of plants in China, particularly in the chemicals sector.
- ❑ Today, the chemicals industry is under pressure due to heightened volatility in crude oil prices and related petrochemical intermediates owing to the Russo-Ukraine conflict.
- ❑ This would also lead to margin pressure for some chemicals companies highly dependent on imports.
- ❑ Deepak Nitrite's business segments are interconnected. As a result, higher margins in one segment may result in lower margins in another. This year has been
- ❑ extremely successful for the BI, PP and phenolics sub-segments, supported by positive industry dynamics.
- ❑ In the fine & specialty chemicals sub-segment (FSC), since most of the contracts are long-term, there is some latency in passing on input costs.
- ❑ Price increases are being deferred tactically in some instances to build relationships and increase wallet shares of customers. The company has either maintained or gained market shares in almost all products.
- ❑ By proactively assessing the market situation and ensuring supplies, the company has passed on the rise in raw material costs in most cases, thereby protecting margins, although with some time lag, the effect of which will be more visible in the year following.

Performance of each segment in FY22

- Operational environment in FY22 was challenging, with escalating costs across value chain. Raw material prices remained elevated together with heightened utility costs including power and fuel. This was in addition to logistical issues that persisted throughout year. Within this backdrop, Deepak Nitrite implemented its planned production strategy effectively and efficiently, to meet its supply commitments, and ensure reliable and steady supplies without much disruption.

Basic Intermediates (BI)

Despite the adverse macro-economic situation and temporary disruption in raw material, the company continues to meet its delivery commitments

Revenue and EBIT grew 66% and 61% respectively to Rs12.6bn and Rs3.1bn in FY22.

Fine & Specialty Chemicals (F&S)

Despite logistic disruptions to elevated RM costs and utilities, F&S chemicals grew 10% y/y to Rs8.5bn while EBIT declined 23%

Due to the nature of contracts in this segment, prices are not immediately passed on, but rather with a time lag.

Performance Products (PP)

Supported by higher realisations in DASDA due to strong demand, revenue and EBIT of performance products grew 74% and 335% y/y respectively to Rs5.3bn and Rs1bn.

Overall volumes in the segment were up 26%

Phenol

Revenue grew 68% y/y to Rs43bn with a 23% EBITDA margin.

The greater contribution resulted from forward integration into value-added derivatives such as IPA.

Isopropyl Alcohol (IPA) contributed 7% to phenolics revenue, with 22% of acetone consumed captively.

Geographical performance

Domestic revenues rose 71% y/y to Rs52.7bn, owing to steadfast demand recovery in key end-user industries as well as benefits accruing from global supply-chain disruptions.

Exports were up 20% due to deepening customer engagements in key regions and the overall shift in the global supply chain on the back of the China+1 strategy

- ❑ Price increases are being deferred tactically in some instances to build relationships and increase wallet shares of customers. The company has either maintained or gained market shares in almost all products.
- ❑ By proactively assessing the market situation and ensuring supplies, the company has passed on the rise in raw material costs in most cases, thereby protecting margins, although with some time lag, the effect of which will be more visible in the year following.

Basic Intermediates (BI)

The BI sub-segment has been the key beneficiary of the shift in global supply chains, and is expected to be further benefited based on a promising demand trajectory.

Fine & Specialty Chemicals (F&S)

Better demand visibility, higher revenues from new multi-year contracts, and the ability to pass on cost increases would aid the performance in the FSC segment, consequently increasing wallet- and market-shares in all key accounts.

Performance Products (PP)

Per management, the growth trajectory is projected to continue due to favorable market dynamics.

Based on the fully integrated approach, the company is poised to capture added demand from key end-use sectors, which have all resumed production to pre-Covid'19 levels.

Phenol

Doubled IPA capacity to 60,000 tons.

Planning to invest in downstream products to sustain business momentum and profitability.

Overall


Growth will be driven by planned expansion projects across SBUs and strategic introduction of numerous downstream chemicals and complex chemical platforms.

Rs15bn capex in new downstream products and sophisticated chemistry platforms as part of the next phase of expansion, thus elevating itself toward the path of solvent majors in the world.

Fine Organic's MDA

Key highlights

- ❑ The global oleochemicals market was valued at \$22.5bn in 2021 and is estimated to touch \$33.9bn by 2027.
- ❑ Household consumption of oleochemical products is expected to increase; thereby vigorously driving the demand for the oleochemicals.
- ❑ The fast-growing demand for biodiesel and the FMCG sector are key determinants driving the oleochemicals market expansion.
- ❑ Further, the growing adoption of oleochemicals by chemical manufacturers to produce bio-surfactants, bio-lubricants and bio-polymers as sustainable alternatives to petrochemicals is a major growth driver.
- ❑ The market is driven by rising consumer demand for natural items such as organic soaps, food additives, cosmetics and so on.
- ❑ Besides, rapid global industrialisation is another key driver of market expansion. Furthermore, manufactures are keen to introduce sustainable oleochemicals and reduce their carbon footprint to create a brand-image of an environmentally responsible businesses.



Source:- Fine Organic- Annual Report FY22

- ❑ Additives constitute an integral part of the plastics sector. They are used to modify properties of plastic products during the compounding and processing stages. Some of the major trends in the plastics sector have been to encourage the use of bio-based raw materials, maximum recycling/reprocessing of used plastics to promote a 'circular' economy and, thereby, successfully address the issues caused by plastics waste. Therefore, the role of plastic additives has become more prominent and imperative

Global Scenario

2021 \$24.6bn
2026 \$30.8bn
CAGR 4.66%

Greater demand for packaging

With increasing populations, rapid urbanisation and rising middle-class incomes, APAC countries are expected to see robust demand for plastic additives in automotives, electronic & electrical goods and other applications.

Global Scenario

The Covid-19 pandemic severely disrupted the overall plastic additives market in 2020.

Consumption started improving in 2021, followed by economic recovery and resumption of manufacturing.

However, pre-pandemic levels of consumption will be attained only by 2023.

Indian Scenario

2021 \$1.19bn
2026 \$1.64bn
CAGR 6.66%

The packaging segment is India's largest user of plastic additives, and is expanding rapidly.

Plastic additives grew during the pandemic from rising demand for food and beverage packaging products not only in India but also worldwide.

Demand drivers

Development of sustainable and value-added plastic additives

Vast demand in packaging applications (flexible/ rigid films/ sheets, rigid bottles & containers)

Consumer goods growth;
Consumer preference shift toward eco-friendly plastic products and rise in use of food packaging and compostable bags

Industry Outlook: Food Additives

- Food additives are used to preserve freshness, taste, texture and appearance of various food items for an extended duration to ensure adequate shelf-life of food products. Therefore, food additives play a critical role in high-volume products such as breads, biscuits and rusks to high-value ready-to-eat food items such as desserts, chocolates, spreads, cheese and more. The mounting demand for packaged/canned food has been positive, translating to greater consumption of food additives in the past, and is expected to continue favorably in coming years as elaborated in the next section, capturing the global situation.

Global Food Additives

4.93% CAGR expected over 2022-27.

Rising demand for processed, packaged and convenience foods

Changing consumer tastes and preferences for ready-to eat Food, boosting the food additives market.

Global food additives
2020 \$36.01bn
2028 \$57.04bn
CAGR 5.7%

Indian Food Additives

2020 \$104.7m
2026 \$159.23m
CAGR 7.25%

In Asian countries such as India, with higher disposable incomes and more engaging lifestyles, demand for packaged, processed and ready-to-eat foods is increasing.

Indian Food Additives

The Indian food and beverage segment is continually looking for additives and ingredient options that aid the nutritive value of food products, have a longer shelf-life, better structure and high stability. Therefore, the use of better and more efficient additives presents growth opportunities to market operators

Indian Food Additives

India has been a prominent milk producer in the world. Thus, demand for flavored milk and re-combined milk, made from milk powder and chocolate milk drives the emulsifier market further in the thriving dairy industry

- ❑ Cosmetic emulsifiers and emollients are used in various personal-care products, generally to mix water with oil. Surface active agents that act as an the interface between two immiscible liquids along with maintaining the stability of the mixture are called emulsifiers. Cosmetic emulsifiers help reduce surface tension between lipophilic and hydrophilic constituents, resulting in finely dispersed mixtures. This, in turn, improves shelf-life and increases performance properties of personal-care products.

Global Cosmetics Market

5.3% CAGR over 2021-27

Growing consumer base due to strikingly greater awareness, rising disposable incomes, surge in cosmetics manufacturing, expanding urbanisation, rapid adoption of cosmetic products among millennials and increasing e-commerce sales.

Indian Scenario

4.23% CAGR over 2021-22

Covid-19 has altered the spending habits of consumers and changed purchase decisions, leading to a slight drop in market growth owing to the lockdown and closing of various retail stores.

Indian Scenario

Nevertheless, enhanced awareness of hygiene and personal wellness has made consumers more concerned about the potential damages of pollution and stress in their current lifestyle; thereby, opting for various cosmetic products as remedies.

Opportunities

Growing demand for various skin-care and hair-care products

Rise in demand for high-value cosmetics

Significant rise in demand for numerous skin-care products

Rise in popularity of natural cosmetic ingredients

- Specialty coating additives play a critical role in coating applications by improving product quality and stability, resulting in maximised benefits in end-applications by imparting overall better quality. Although the use of these additives is typically modest, the functional improvement is noteworthy. These additives are used in the printing process to provide the necessary slip and anti-blocking qualities, resulting in a high-quality printed surface for an extended period. Printed surfaces often include various materials such as rubber, cardboard, papers and metals. Inks are also used in printing for plastic cards and films among others.

Global Coating market

5.5% CAGR over 2021-30

Coating additives is anticipated to grow in the automotive sector and paint industry, among others.

The chemical formulation of coating additives is being increasingly well-accepted due to the performance enhancements that these materials offer at the end-application.

Indian Scenario

India has emerged as one of the largest consumers and producers of inks in the Asia Pacific region.

It is one of the fastest-growing printing ink markets in the world, spurred by the rapid expansion of domestic print markets.

Indian Scenario

Demand for industrial coatings can be propelled by the rapid industrialisation in a developing economy like India.

This will consequently be a significant driving factor for this market..

Opportunities

Growing demand for e-commerce business, increasing applications, and technological advancements

Increasing demand for plastics

Growing packaging sales

Rising influence of eco-friendly coating additives

SRF's MDA

Key highlights

FY22 performance, business-wise. Outlook FY23

ANANDRATHI

The **chemicals** business comprises two product segments, fluorochemicals and specialty chemicals. In FY22, it grew 43.8% y/y, to Rs52.4bn.

Specialty Chemicals

Despite being faced with challenges (rising crude prices, logistics issues, and global shortage of some inputs which increased prices of key raw materials) SC maintained its growth momentum .

Launched several agro and pharma intermediates. Further, enhanced production capacities of several plants, while reducing consumption of some RMs, thereby offsetting to some extent the impact of higher RM prices.

Specialty Chemical Expansion

Enhanced market positioning by commissioning three dedicated plants.

Obtained approval for a fourth MPP and a new pharma intermediates plant in FY22

Chemical Technology Group

R&D on 57 molecules and many products were taken up for process development.

More than 20 molecules were taken up for scaled-up studies; 70% were commercially produced at multi-purpose and dedicated plants.

CTG filed 52 patents in FY22, (total 361). 21 were granted in FY22 (total patents granted, 114)

Outlook

Focused on agrochemicals and pharmaceuticals, where business collaborates with major global innovators for process development, commercialisation, and production of complex, new-age molecules having downstream application in agrochemicals and pharmaceuticals.

FY22 performance, business-wise. Outlook FY23

The **chemicals** business encompasses two product segments, fluorochemicals and specialty Chemicals. In FY22, this business grew 43.8% y/y to Rs52.4bn.

Fluorochemicals

Key issues in FY22:
Semi-conductor shortages,
Supply-chain issues,
Force majeure by suppliers

This hit the domestic
refrigerant
market.

International markets,
however, were strong
throughout the year.
SRF grabbed this
opportunity, resulting in
exports rising considerably.

Industrial Chemicals

Growth was supported
by an expansion in the
pharma and
agrochemicals
segments.

SRF maintained its share
and
launched one product

Dymel® /propellants
saw increased market
share
along with entry to new
regions.

Outlook

Despite a disrupted
recovery, higher inflation,
rise in energy & RM prices,
and supply-chain
bottlenecks, SRF anticipated
an increase in demand on
account of pent-up
refrigerants demand in the
home market and in
industrial chemicals.

Exports expected to be
stable. With its present
reasonable share in the US
and a bright outlook, it
expects to register a healthy
performance.

Outlook

Overall, the business is
anticipated to improve
on the commissioning of
new plants like CMS,
PTFE, along with other
cost-improvement
initiatives including
supply-chain
stabilisation.

FY22 performance, business-wise. Outlook FY23

Technical Textiles FY22 started on a difficult note with lockdown restrictions due to the second wave of Covid-19. Further, business were faced with supply-chain challenges but no plants were shuttered due to shortages. Revenue of the segment grew 68% y/y to Rs21bn on the highest sales volumes of belting fabrics and polyester industrial yarn. This partially offset weak demand for nylon tyre-cord fabrics.

Tyre-Cord Fabrics

Good demand in H1 FY22 came from pent-up demand in the replacement and OEM markets

However, in H2, the markets fell steeply because of low original-equipment (OE) tyre sales and a subdued replacement market

This led to lower tyre-cord-fabric capacity-utilisation in H2 FY22

Belting Fabrics

Key end-user industries (steel, cement, coal, power generation) grew well in FY22, supporting volume growth.

Commercialised a few high-end value-added products (VAPs)

Besides, completed approved capacity-expansion projects in FY22.

Polyester Industrial Yarn

Greater volumes in FY22

Despite an unfavourable product mix, performance of the division was stable.

The PIY division will further strengthen its position in FY23 and focus on a profitable product-sales mix.

Outlook

Expecting positive trends like a bright outlook for the Indian economy, infrastructure development, and agricultural growth would be positive for Technical Textiles

Demand would boom, leading to greater capacity utilisation in FY23.

FY22 performance, business-wise. Outlook FY23

Packaging Films revenue grew 45% y/y to Rs48bn. Domestic and international plants' performances were strong and contributed to overall growth. SRF allocated Rs4.25bn to set up an aluminium-foil manufacturing plant near Indore, MP, expected to be commercialised in the next 20 months.

Packaging Films

FY22 has been a good year for packaging films, supported by increased demand for food packaging.

All plants maximised production, and kept costs in check

Expansion of value-added products

Launched several products and grew overall BOPET VAP sales significantly y/y.

Started the BOPP film plant in Thailand despite severe restrictions and limited availability of supplier personnel and field experts on-site due to the Covid-19 pandemic.

Capex

Working on the coming BOPP film line in India, which is progressing well.

Timely vertical start-up of this line will be an important focus area in FY23.

Outlook

Several new film lines have been announced in India and globally. In future, there might be an oversupplied market, resulting in pressure on profitability.

The focus would be on keeping a close watch on the macro-economic situation and remaining flexible enough to adopt a strategy accordingly.

Other Businesses SRF retains market leadership in coated fabrics, with a high-volume share driven by improved sourcing initiatives and plant efficiency. In laminated fabrics, it retained its price and volume leadership, operating at full capacity, and attaining its highest sales in Q4. However, realisations were impacted by the continuing surplus supply situation.

Coated Fabrics

Business was impacted in Q1 FY23 by Covid-19.

Demand for coated fabrics recovered during 9M FY22 as restrictions on events and outdoor activities eased.

Laminated Fabrics

SRF continued its price and volume leadership in laminated fabrics by running at full capacity and achieving its highest sales.

Margins under pressure

Margins in laminated fabrics were under pressure as higher costs could not be passed on completely to customers due to excess supply.

Outlook

Demand expected to pick up as all restrictions on outdoor events have been lifted.

On the overall revival in economic activity, the performance is anticipated to be healthy.

In both the businesses, the focus will be on increasing sales and working on various cost-reduction measures.

Atul's MDA

Key highlights

FY22 performance, business-wise. Outlook FY23

Life-Science Chemicals

Sales (Rs bn)	14.5bn in FY22	11.2bn in FY21	+29% y/y
Share in total sales (%)	29	32	3

Crop Protection

Revenue: Rs9.3bn, up 50% y/y,
volume growth ~17%

Domestic sales: Rs3.7bn,
up 27% y/y

India bulk sales: Rs2bn,
up 39% y/y

India retail sales: Rs1.7bn,
up 15% y/y

Exports: Rs5.5bn, up 70% y/y.

Completed three & undertook
two projects for implementation.

Global Industry size

Crop protection chemicals
\$65bn, to grow to \$73.8bn
by 2026 at a 2.5% CAGR

Outlook

Improve internal efficiencies
and working capital

Promote retail sales

Expand the product range
and secure more registrations

Evaluate investment
opportunities
in vertical integration.

Risk and Concerns

High cost of some of the
main raw materials could
impact profitability of
the business.

Adverse weather

Forex fluctuations

High registration cost

FY22 performance, business-wise. Outlook FY23

Life-Science Chemicals

Sales (Rs bn)	14.5bn in FY22	11.2bn in FY21	+29% y/y
Share in total sales (%)	29	32	3

Pharmaceuticals & Aromatics

Segment revenue: Rs5.1 bn,
up 2% y/y,

Domestic sales: Rs3.1 bn, up
2% y/y

Exports: Rs2bn, up 2% y/y.

Sales of Atul Bio-Science:
Rs1.26bn, down 12% y/y

Completed one project

Global Industry size

Pharma: \$1.45trn, of which
conventional pharma \$1.1trn.
Of this, API \$160bn

Biologics estimated to
contribute about 52%
of sales of the top-100
products by 2022
Oncology will be the largest
therapy, with sales at about
a 12.7% CAGR.

Outlook

Increase manufacturing
efficiencies

De-bottleneck and add
capacities

Introduce products

Form long-term strategic
alliances with other
companies.

Risk and Concerns

Prices of and demand for
some products have been
inconsistent and are likely
to vary widely in the short
run.

Fluctuations in foreign
exchange may impact sales.

FY22 performance, business-wise. Outlook FY23

Performance Chemicals and Other Chemicals

Sales (Rs bn)	34.5bn in FY22	23.4bn in FY21	+49% y/y
Share in total sales (%)	71	68	3

Aromatics

Segment revenue
Rs7.8bn, up 40% y/y

Volume growth ~9% y/y

Domestic sales Rs2.5bn,
up 19% y/y

Exports: Rs5.3bn,
up 52% y/y.

Completed one project

Global Industry size

para-Cresol (a key product)
69,000 tons,
growing 2%

Global fragrance industry
\$15bn, growing 5%

Global personal-care
\$467bn;
of which, personal-care
ingredients \$27bn, growing
5%

Outlook

Broaden market reach

Increase manufacturing
efficiencies

De-bottleneck, add
capacities

Introduce products

Evaluate inorganic
growth opportunities.

Risk and Concerns

Fluctuations in foreign
exchange may
impact sales realisations.

FY22 performance, business-wise. Outlook FY23

Performance Chemicals and Other Chemicals

Sales (Rs bn)	34.5bn in FY22	23.4bn in FY21	+49% y/y
Share in total sales (%)	71	68	3

Bulk Chemicals

Segment revenue: Rs3.1bn, up 9% y/y

Volume growth ~9%

Domestic sales: Rs1.8bn, up 17% y/y

Exports: Rs1.3bn, flat y/y.

Global Industry size

Resorcinol (a key product) \$578m, growing 2.5%

Global tyre industry \$246bn, growing 2.7%

Global chlor-alkali industry \$53bn, growing 2.9%

Tyre industry projected to grow, supported by resurgence in Asia-Pacific.

Outlook

Captive consumption of bulk chemicals is expected to grow as the company expands manufacturing capacities of various products.

Greater manufacturing efficiencies

De-bottlenecking and adding capacities

Adding downstream products

Widening market reach

Risk and Concerns

Demand and prices of bulk chemicals are cyclical.

Foreign exchange fluctuations may impact sales realisations.

FY22 performance, business-wise. Outlook FY23

Performance Chemicals and Other Chemicals

Sales (Rs bn)	34.5bn in FY22	23.4bn in FY21	+49% y/y
Share in total sales (%)	71	68	3

Colors

Revenue Rs8bn, up 36% y/y

Volume growth ~25%

India sales Rs4bn, up 27% y/y

Exports sales Rs4bn, up 45% y/y.

Rudolf Atul Chemicals (JV)
Revenue Rs1.2bn, up 36% y/y

Industry size

Global textile dyestuff \$6.2bn, growing 3%

Global high performance pigments \$5.4bn, growing 4%

China continues to be the largest manufacturer of dyes followed by India.

Outlook

Increase in manufacturing & WC efficiencies

Introducing new dyes, pigments, textile chemicals and products for non-textile applications

investing in newer capacities of existing and new products

Widening market reach

Risk and Concerns

Treatment costs are expected to remain high because of stricter regulatory norms and increasing demand for sustainable products from user industries

Foreign exchange fluctuations may impact sales realisations.

FY22 performance, business-wise. Outlook FY23

Performance Chemicals and Other Chemicals

Sales (Rs bn)	34.5bn in FY22	23.4bn in FY21	+49% y/y
Share in total sales (%)	71	68	3

Polymers

Revenue Rs15.5bn, up 76% y/y

Volume growth ~29%

India sales Rs9.5bn, up 59% y/y

India bulk sales Rs7.5bn, up 63% y/y

India retail sales, Rs1.9bn, up 43% y/y

Exports Rs6bn, up 113% y/y.

Industry size

Global epoxy resins and curing agents \$12bn, growing 3%

Indian epoxy resins and curing agents \$380m, growing 6%

Global sulfones (curing agents) \$393m, growing 6%.

Outlook

Increase in manufacturing & WC efficiencies

De-bottlenecking and adding capacities

Introducing products

Widening market reach

Risk and Concerns


Cheaper imports

Fresh entrants will keep the market competitive and margins under pressure.

Since the two main RMs, Bisphenol-A and Epichlorohydrin, are imported, fluctuations in foreign exchange may cut into margins

Contingent liabilities as percent of net worth

- ❑ Contingent liabilities (incl. capital commitments) as percent of net worth averaged 8% in FY22 (vs 17% in FY15).
- ❑ This substantially increased in the case of **Navin** in the last two years from the steep rise in its capital commitments.
- ❑ **SRF's** average contingent liabilities as percent of net worth were 14%, followed by Deepak Nitrite, Vinati, Navin and Atul at 13%, 10.1%,9.9% and 9.3% each.
- ❑ **Fine Organic's** contingent liabilities as percent of net worth were lowest 5.4%.



☐ Navin

- Shifted manufacturing units closer to carbon neutrality.
- Treated wastewater from the community
- Wastewater-treatment plant recycled to conserve freshwater at its Surat unit
- Recycled 2,000 kl of wastewater per day in the cooling towers
- In a few process plants, installed two-stage scrubbing units to eliminate fugitive emissions
- Waste streams were converted into calcium chloride and sold to end-users, enhancing waste re-use
- Took an initiative to supply a few finished products in bulk packaging, eliminating packaging waste.

☐ SRF

- Energy saved through energy-efficient initiatives: 20 TJ
- Energy consumed from renewables and biomass: 914 TJ
- Recycled water consumption: 1,696m litres.
- Reduction in GHG emissions and less use of fresh resources with biodiversity preservation

☐ Atul

- Collected 259 tonnes of waste. of which 196 tonnes were recycled
- Completed 86 identified air-emission-control projects.
- Commissioned a new effluent treatment plant at Atul South site to augment treatment capacity.
- Installed multiple-effect evaporators as part of the zero-liquid-discharge project at Atul North site.

Focus on ESG parameters, Environment Conservation Initiatives, contd.

❑ Fine Organic

- Shifted from using furnace oil to natural gas to reduce CO₂ emissions and eliminate SO_x levels. All plants are zero-liquid-discharge.
- Developed and maintained a “green” belt and landscaping around facilities by renting open spaces/areas from MIDC to improve O₂ release into the surrounding environment.
- All warehouses use renewable energy like solar power in the form of “sky pipes”.
- Plastic waste generated at facilities is collected and sent to authorised recyclers.

❑ Vinati Organics

- Commissioned a 14MW solar plant. At present, 50% of energy required is obtained from renewable energy
- Reduced CO₂ emission by over 15% in the past few years by strengthening boiler operations, which has led to less coal consumption
- Increased condensate recovery and recycled DM water in its co-gen power plant to reduce coal and DM water consumption

❑ Deepak Nitrite

- To reduce emissions, Deepak installed electrostatic precipitators, bag filters, and scrubber systems in boilers throughout the year.
- It replaced older inefficient boilers with newer ones that will emit significantly less pollution.
- Primary focus is on recycling water into operations to reduce reliance on fresh water. It plans zero-liquid-discharge (ZLD) for facilities to achieve this. As it does not harvest water directly from any source, its operations have no direct impact on any water body. In total, 373,113 kl were recycled.
- Waste management is imperative. The company converted bye-products into value-added products, reducing packaging waste by greater efficiency and developing products from waste.
- 32% reduction in specific GHG emissions

Focus on ESG parameters, Social Initiatives- CSR


All companies were spending similar or higher amount on CSR activities than mandated by law except Vinati and Fine Organic. Fine Organic had Rs56.9m in a separate bank account on 31st Mar'22 to be spent on CSR. Vinati transferred Rs41.8m in FY21 and Rs34.2m in FY22 to a separate bank account. Atul had Rs43.5m in as separate bank account on 31st Mar'22.

Particulars (Rs m)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22
Navin								
Required to be spent	30.0	14.2	7.6	22.4	31.5	37.5	43.5	52.3
Spent	13.2	19.5	30.2	29.7	32.9	37.9	56.8	52.8
Deficit / (Excess)	16.9	-5.3	-22.6	-7.3	-1.4	-0.4	-13.3	-0.5
SRF								
Required to be spent	77.1	65.0	75.8	95.6	103.8	116.3	132.5	186.1
Spent	44.2	87.5	76.0	50.0	103.8	120.0	105.5	186.8
Deficit / (Excess)	32.9	-22.5	-0.2	45.6	-	-3.7	27.0	-0.7
Atul								
Required to be spent	39.5	51.4	65.9	73.5	78.8	95.8	124.0	148.7
Spent	39.5	53.1	66.0	73.9	79.0	96.0	124.1	105.4
Deficit / (Excess)	-	-1.7	-0.1	-0.4	-0.2	-0.2	-0.1	43.2
Fine Organic								
Required to be spent				21.7	26.3	33.6	39.8	39.8
Spent				-	3.3	45.5	32.1	23.6
Deficit / (Excess)				21.7	23.0	-11.9	7.7	16.2
Vinati Organics								
Required to be spent	20.9	27.0	32.6	37.7	39.6	36.7	70.2	79.0
Spent	20.6	26.6	21.5	6.9	28.0	17.8	28.5	44.8
Deficit / (Excess)	0.2	0.4	11.1	30.8	11.6	18.9	41.8	34.2
Deepak Nitrite								
Required to be spent	9.2	12.2	16.6	17.9	21.3	30.3	74.4	98.7
Spent	7.6	15.8	16.6	22.5	25.0	34.8	74.4	99.2
Deficit / (Excess)	1.6	-3.6	-	-4.6	-3.7	-4.5	-	-0.5







Focus on ESG parameters: Governance

Particulars	Vinati	Atul	Navin	Deepak	SRF	Fine Organic
Board Composition (No. of Persons)	8	11	12	12	10	10
Board Independence	50%	55%	75%	50%	60%	50%
Chairman	Vinod Saraf	S SLalbhai	Vishad P. Mafatlal	Deepak C. Mehta	Ashish Bharat Ram	Mukesh Shah
MD	Vinati Saraf Mutreja	S S Lalbhai	Radhesh R. Welling	Deepak C. Mehta	Ashish Bharat Ram	Mukesh Shah
Board Composition (Position)	1 executive chairman 1 MD and CEO 2 whole-time directors 4 non-executive, independent directors.	1 chairman and MD, 1 MD, 2 WTD, 1 non-executive director 6 non-executive independent directors	1 MD, 1 chairman 1 non-executive, non-independent director 9 non-executive independent	3 executive directors, 3 non-executive directors, 6 non-executive, independent directors	1 chairman 3 executive promoters 6 independent directors	1 chairman 5 independent directors, 4 executive directors
Experience of Board	~75% of Board members have more than 30 years' experience	~75% of Board members have more than 30 years' experience	~70% of Board members have more than 30 years' experience	75% of Board members have more than 30 years' experience	More than 75% of Board members have more than 30 years' experience	More than 75% of Board members have more than 30 years' experience
Average Directors' age	~50% of the Board averages 50 years and above	Complete Board averages 50 years and above	66 years	~75% of the Board is averages 50 years and above	~75% of the Board average 50 years and above	More than 75% of the Board averages 50 years and above
Women Directors	4, Vinati is among 0.5% of the listed entities in India to have four or more women on the Board	1	2	1	1	1
CEO/MD a member of the compensation committee	No	No	No	No	No	Yes, Mukesh Maganlal Shah is member of Remuneration Committee
CEO/MD/promoter a member of the audit committee	No	No	No	No	No	Yes, Jayen Ramesh Shah, CEO is member of Audit Committee
Auditor	M.M. Nissim & Co., LLP	Deloitte Haskins & Sells, LLP	Price Waterhouse Chartered Accountants, LLP	Deloitte Haskins & Sells	BSR & Co.	B Y & Associates,
Rotation of Auditors	Re-appointed auditor for the next five years	Re-appointed auditor for the next five years	Re-appointed auditor for the next five years	Re-appointed auditor for the next five years	1-year-term pending	Re-appointed auditor for the next three years

- ❑ The dividend-payout ratio average 17% in the last eight years.
- ❑ Navin and Fine Organic averaged the highest dividend payout over FY15-FY22, 23% and 22% respectively.
- ❑ Deepak Nitrite's dividend-payout ratio was 16% over FY15-18
- ❑ Atul's dividend-payout ratio averaged 11%, while SRF and Vinati paid 15% of earnings as dividend in the last eight years




Dividend Payout



Promoters' shareholdings

- ❑ In the last eight years, only Vinati's promoter raised its stake from 72.3% on 31st Mar'15 to 74.1% on 31st Mar'22
- ❑ Fine Organic's promoter-holding was 75%, post listing in FY18.
- ❑ All other companies' promoter-holdings declined by an average of 6%
- ❑ Navin's promoter-holding fell steeply to 29.7% on 31st Mar'22 vs 38.8% on 31st Mar'15.
- ❑ Deepak Nitrite's promoter-holding declined 706bps to 45.7% on 31st Mar'22.
- ❑ SRF's promoter-holding changed by 1.65% to 50.7% on 31st Mar'22 compared to 52.4% at 31st Mar'15.



Related Party transactions;not material

- No material transactions with related parties. It remained to 3/4% of total sales and Raw material cost over last eight years for these companies.

SRF	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales	(Rs m)								
Enterprises over which KMP have significant influence	-	-	-	-	-	2.5	-	0.4	No major transaction with related parties.
% of Sales	-	-	-	-	-	0.0	-	0.0	
Purchases									
Enterprises over which KMP have significant influence	-	-	-	-	-	-	-	-	
% of RMC	-	-	-	-	-	-	-	-	

Vinati Organics	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales	(Rs m)								
Viral Alkalis	0.2	0.1	0.2	0.2	12.5	1.7	0.5	0.1	Vinati Organic's sales to related parties was negligible over FY15-20. It increased to 1% in FY21 and FY22 (Rs109m and Rs164m) as it started to sell to Veeral Additives. Its purchase as % of RMC was 2% in FY21 and 0.2% in FY22. Its major related-party transaction was a Rs1.2bn loan to Veeral Additives Pvt Ltd. It was Rs1.3bn inFY21.
Veeral Additives Pvt. Ltd.					-	3.3	108.9	163.6	
% of Sales	0.0	0.0	0.0	0.0	0.1	0.0	1.1	1.0	
Purchases									
Viral Alkalis Ltd			-	10.2	34.4	40.8	67.8	12.9	
Veeral Additives Pvt. Ltd.					-	1.5	9.9	2.5	
% of RMC	-	-	-	0.3	0.7	1.0	2.0	0.2	
Loans to									
Veeral Additives Pvt. Ltd.						-	1,319	1,205	

Atul	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales	(Rs m)								
Sale of goods to JV				27.5	38.5	30.1	21.0	37.3	Atul's purchases from related parties were 0.6% to 1.3% of RMC in the last eight years. Sales to related parties were less than 1%.
% of sales	-	-	-	0.1	0.1	0.1	0.1	0.1	
Purchases									
With JVs				3.0	2.4	1.9	0.9	0.1	
Entity over which control exercised by JVs	153.3	134.4	144.2	233.3	140.0	117.2	164.3	159.1	
% of RMC	1.1	1.0	1.0	1.3	0.7	0.6	1.0	0.6	

Related Party transaction;not material

Navin	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales	(Rs m)								
Convergence Chemicals Pvt Ltd	-	-	-	23.9	95.6	102.1	103.8	-	Navin Fluorine's sales and purchases to related parties were less than 1% of sales and raw material costs in the last eight years. No material transactions with related parties.
Nocil	0.3	0.1	0.1	-	-	-	-	-	
% of Sales	0.0	0.0	0.0	0.3	1.0	1.0	0.9	-	
Purchases									
Convergence Chemicals Pvt Ltd	-	-	-	-	7.9	6.9	-	-	
% of RMC	-	-	-	-	0.2	0.1	-	-	

Fine Organic	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales	(Rs m)								
OleoFine Organics SDN. BHD.			53.1	52.5	40.6	45.0	60.8	87.2	Fine Organic's purchases and sales with related parties were 0-2% in the last five years.
OleoFine Organics (Thailand) Co., Ltd.			20.1	31.0	49.0	48.3	8.7	-	
Fine Organics Industries			41.0	32.6					
Fine Zeelandia Pvt Ltd			1.5	0.0	71.7	126.3	129.7	164.3	
% of Sales			1.5	1.4	1.5	2.1	1.8	1.3	
Purchases									
Fine Zeelandia Private Ltd			0.0	-	-	0.5	-	-	Its highest sales to related parties were Rs164m, 1.3% of sales to Fine Zeelandia Pvt Ltd (JV). No purchase from any related parties during the year.
Fine Organics Industries			22.3	136.4	-	-	-	-	
OleoFine Organics s SDN. BHD.			0.3	2.5	6.6	-	0.8	-	
% of RMC			0.4	2.1	0.1	0.0	0.0	-	

Related Party transaction;not material

Deepak Nitrite	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	Remark
Sales				(Rs m)					
Deepak Novochem Technologies	1.3	6.4	71.3	90.2	69.6	-	211.5	181.2	
Deepak Phenolics	-	-	-	-	-	-	96.7	17.2	
Deepak Fertilisers & Petrochemicals Corp.	-	-	-	-	-	-	-	12.3	
% of Sales	0.0	0.0	0.5	0.5	0.3	0.0	0.7	0.3	
Purchases									
Deepak Fertilisers & Petrochemicals Corp.	628.5	708.3	820.2	1,024.5	790.0	633.4	771.6	1,246.4	Deepak Nitrite's purchases from related parties, mainly Deepak Fertilizers & Petrochemicals Corp., were ~3.2% of RMC in FY22.
Deepak Novochem Technologies	22.4	5.5	-	3.4	-	-	-	-	
Deepak Phenolics	-	-	-	-	-	-	22.6	58.0	
% of RMC	7.6	8.6	9.7	9.9	4.8	2.7	3.5	3.2	It averaged 9% over FY15-FY18, declining to 3.5% over FY19-FY22.
Purchase of Capital assets									
Deepak Fertilisers & Petrochemicals Corp	-	-	-	-	-	1,171.1	-	-	Its sales to related parties were less than 1% over the last eight years.
Interest paid to related parties									
Storewell Credits & Capital Pvt Ltd	-	-	14.8	24.2	22.2	7.3	-	-	
Deepak C. Mehta	-	-	3.9	7.3	2.0	-	-	-	
Loans from related parties									
Storewell Credits & Capital Pvt Ltd	-	-	230.0	-	-	-	-	-	
Deepak C. Mehta	-	-	70.0	-	-	-	-	-	

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)	Buy	Hold	Sell
Large Caps (>US\$1bn)	>15%	5-15%	<5%
Mid/Small Caps (<US\$1bn)	>25%	5-25%	<5%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may: (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind. Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer Marco Polo Securities Inc. Transactions in securities discussed in this research report should be effected through Marco Polo Securities Inc.

- ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- As of the publication of this report, ARSSBL does not make a market in the subject securities.
- ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2022. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097. Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 |
CIN: U67120MH1991PLC064106.